Intra-Cellular Therapies, Inc. (ITCI) NASDAQ
$76.38 1.16 (1.54%)
Market Cap: $8.07B
As of 09/13/24 11:28 AM EDT. Market open.
Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ
$76.38
1.16 (1.54%)
Market Cap: $8.07B
As of 09/13/24 11:28 AM EDT. Market open.
Add to Portfolio
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Sharon Mates Ph.D.
Full Time Employees
610
CEO Compensation (Base)
$793,638
CEO Compensation (Total)
$7.25M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Sharon Mates Ph.D.
Full Time Employees
610
CEO Compensation (Base)
$793,638
CEO Compensation (Total)
$7.25M
Address
430 East 29th Street, NY, New York, 10016.
PRICE CHART FOR INTRA-CELLULAR THERAPIES, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$75.55
Previous Close
$75.22
Days Range
$75.55 - $76.59
52 week range
$45.50 - $84.89
Volume
109,728
Avg. Volume (30 days)
1,031,133
Market Cap
$8.07B
Dividend Yield
-
P/E
(88.81)
Shares Outstanding
105,667,000
Open
$75.55
Previous Close
$75.22
Days Range
$75.55 - $76.59
52 week range
$45.50 - $84.89
Volume
109,728
Avg. Volume (30 days)
1,031,133
Market Cap
$8.07B
Dividend Yield
-
P/E
(88.81)
Shares Outstanding
105,667,000
FINANCIAL STATEMENTS FOR INTRA-CELLULAR THERAPIES, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR INTRA-CELLULAR THERAPIES, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Mates Sharon | Chairman and CEO | Aug 30, 2024 | Option Exercise | $12.73 | 34,396 | 437,861 | 1,104,725 | Aug 30, 2024, 06:01 PM |
| Mates Sharon | Chairman and CEO | Aug 29, 2024 | Option Exercise | $12.73 | 35,604 | 453,239 | 1,105,933 | Aug 30, 2024, 06:01 PM |
| Mates Sharon | Chairman and CEO | Aug 30, 2024 | Sale | $72.84 | 34,396 | 2,505,351 | 1,076,522 | Aug 30, 2024, 06:01 PM |
| Mates Sharon | Chairman and CEO | Aug 29, 2024 | Sale | $72.57 | 35,604 | 2,583,884 | 1,076,101 | Aug 30, 2024, 06:01 PM |
| Mates Sharon | Chairman and CEO | Aug 28, 2024 | Option Exercise | $17.57 | 32,699 | 574,521 | 1,103,028 | Aug 28, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 27, 2024 | Option Exercise | $17.57 | 40,513 | 711,813 | 1,110,842 | Aug 28, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 26, 2024 | Option Exercise | $17.57 | 22,713 | 399,067 | 1,093,042 | Aug 28, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 27, 2024 | Sale | $73.58 | 40,513 | 2,981,056 | 1,087,185 | Aug 28, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 26, 2024 | Sale | $74.59 | 22,713 | 1,694,229 | 1,070,329 | Aug 28, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 28, 2024 | Sale | $72.75 | 32,699 | 2,378,801 | 1,070,569 | Aug 28, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 22, 2024 | Option Exercise | $17.57 | 39,380 | 691,907 | 1,109,709 | Aug 23, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 21, 2024 | Option Exercise | $17.57 | 53,013 | 931,438 | 1,123,342 | Aug 23, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 23, 2024 | Option Exercise | $17.57 | 28,680 | 503,908 | 1,099,009 | Aug 23, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 22, 2024 | Sale | $74.68 | 39,380 | 2,940,802 | 1,074,698 | Aug 23, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 21, 2024 | Sale | $75.65 | 53,013 | 4,010,501 | 1,079,208 | Aug 23, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Aug 23, 2024 | Sale | $74.46 | 28,680 | 2,135,435 | 1,070,329 | Aug 23, 2024, 06:00 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Aug 16, 2024 | Option Exercise | $36.89 | 18,714 | 690,359 | 48,414 | Aug 20, 2024, 06:03 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Aug 16, 2024 | Sale | $75.08 | 18,714 | 1,405,047 | 29,700 | Aug 20, 2024, 06:03 PM |
| VAN NOSTRAND ROBERT L | Director | Jun 28, 2024 | Option Exercise | $68.49 | 83 | 5,685 | 11,340 | Jul 02, 2024, 08:00 PM |
| RIGGS RORY B | Director | Jun 28, 2024 | Option Exercise | $68.49 | 262 | 17,944 | 116,862 | Jul 02, 2024, 08:00 PM |
| RIGGS RORY B | Director | Jun 24, 2024 | Option Exercise | $16.86 | 20,000 | 337,200 | 121,062 | Jun 25, 2024, 06:04 PM |
| RIGGS RORY B | Director | Jun 24, 2024 | Sale | $75.57 | 4,462 | 337,193 | 116,600 | Jun 25, 2024, 06:04 PM |
| VAN NOSTRAND ROBERT L | Director | Jun 18, 2024 | Option Exercise | $16.86 | 20,000 | 337,200 | 29,690 | Jun 21, 2024, 06:00 PM |
| VAN NOSTRAND ROBERT L | Director | Jun 18, 2024 | Sale | $75.91 | 20,000 | 1,518,199 | 20,799 | Jun 21, 2024, 06:00 PM |
| Mates Sharon | Chairman and CEO | Apr 24, 2024 | Option Exercise | $17.26 | 20,020 | 345,618 | 1,070,329 | Apr 25, 2024, 05:08 PM |
| VAN NOSTRAND ROBERT L | Director | Mar 31, 2024 | Option Exercise | $69.20 | 79 | 5,467 | 9,690 | Apr 02, 2024, 04:15 PM |
| RIGGS RORY B | Director | Mar 31, 2024 | Option Exercise | $69.20 | 260 | 17,992 | 99,495 | Apr 02, 2024, 04:15 PM |
| RIGGS RORY B | Director | Mar 20, 2024 | Option Exercise | $18.56 | 20,000 | 371,200 | 99,235 | Mar 22, 2024, 04:12 PM |
| Mates Sharon | Chairman, President & CEO | Mar 11, 2024 | Sale | $65.21 | 20,565 | 1,341,123 | 1,056,333 | Mar 11, 2024, 08:33 PM |
| Mates Sharon | Chairman, President & CEO | Mar 07, 2024 | Sale | $66.50 | 40,712 | 2,707,277 | 1,059,063 | Mar 11, 2024, 08:33 PM |
| Hineline Lawrence J. | SVP of Finance, CFO | Mar 10, 2024 | Option Exercise | $56.73 | 4,539 | 257,497 | 4,539 | Mar 11, 2024, 08:33 PM |
| Hineline Lawrence J. | SVP of Finance, CFO | Mar 11, 2024 | Sale | $65.96 | 10,121 | 667,587 | 1,129 | Mar 11, 2024, 08:33 PM |
| Hineline Lawrence J. | SVP of Finance, CFO | Mar 07, 2024 | Sale | $66.60 | 13,132 | 874,560 | 6,618 | Mar 11, 2024, 08:33 PM |
| Halstead Michael | EVP and General Counsel | Mar 11, 2024 | Sale | $65.97 | 7,345 | 484,537 | 1,238 | Mar 11, 2024, 08:32 PM |
| Halstead Michael | EVP and General Counsel | Mar 07, 2024 | Sale | $66.15 | 13,132 | 868,698 | 220 | Mar 11, 2024, 08:32 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Mar 07, 2024 | Sale | $66.57 | 13,132 | 874,179 | 34,196 | Mar 11, 2024, 08:31 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Mar 11, 2024 | Sale | $65.61 | 7,345 | 481,931 | 32,742 | Mar 11, 2024, 08:31 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Mar 11, 2024 | Sale | $65.59 | 3,712 | 243,482 | 21,336 | Mar 11, 2024, 08:31 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Mar 07, 2024 | Sale | $66.56 | 6,450 | 429,308 | 18,892 | Mar 11, 2024, 08:31 PM |
| VAN NOSTRAND ROBERT L | Director | Feb 27, 2024 | Option Exercise | $18.56 | 20,000 | 371,200 | 29,611 | Feb 28, 2024, 07:41 PM |
| VAN NOSTRAND ROBERT L | Director | Feb 27, 2024 | Sale | $72.93 | 20,000 | 1,458,650 | 19,960 | Feb 28, 2024, 07:41 PM |
| Halstead Michael | EVP and General Counsel | Feb 26, 2024 | Sale | $69.53 | 7,907 | 549,784 | 7,607 | Feb 27, 2024, 08:00 PM |
| Hineline Lawrence J. | SVP of Finance, CFO | Feb 26, 2024 | Option Exercise | $36.89 | 5,882 | 216,987 | 5,882 | Feb 27, 2024, 08:00 PM |
| Hineline Lawrence J. | SVP of Finance, CFO | Feb 26, 2024 | Sale | $69.43 | 13,337 | 925,961 | 7,155 | Feb 27, 2024, 08:00 PM |
| Mates Sharon | Chairman, President & CEO | Feb 26, 2024 | Sale | $69.79 | 22,590 | 1,576,464 | 1,072,299 | Feb 27, 2024, 07:59 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Feb 26, 2024 | Sale | $70.17 | 4,112 | 288,534 | 12,200 | Feb 27, 2024, 07:58 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Feb 26, 2024 | Sale | $70.13 | 7,907 | 554,491 | 37,407 | Feb 27, 2024, 07:58 PM |
| MARCUS JOEL S | Director | Feb 26, 2024 | Option Exercise | $48.93 | 36,757 | 1,798,678 | 65,990 | Feb 27, 2024, 07:57 PM |
| MARCUS JOEL S | Director | Feb 26, 2024 | Sale | $68.68 | 26,328 | 1,808,253 | 57,619 | Feb 27, 2024, 07:57 PM |
| Halstead Michael | EVP and General Counsel | Feb 02, 2024 | Sale | $66.42 | 11,860 | 787,719 | 714 | Feb 05, 2024, 06:13 PM |
| Mates Sharon | Chairman, President & CEO | Feb 02, 2024 | Sale | $67.07 | 33,885 | 2,272,693 | 1,067,759 | Feb 05, 2024, 06:10 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Feb 02, 2024 | Sale | $67.15 | 11,860 | 796,367 | 36,604 | Feb 05, 2024, 06:07 PM |
| Hineline Lawrence J. | SVP of Finance, CFO | Feb 02, 2024 | Sale | $66.62 | 11,183 | 745,037 | 185 | Feb 05, 2024, 06:05 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Feb 02, 2024 | Sale | $67.19 | 6,167 | 414,355 | 9,540 | Feb 05, 2024, 06:02 PM |
| Mates Sharon | Chairman, President & CEO | Jan 17, 2024 | Option Exercise | $16.86 | 48,084 | 810,696 | 1,098,393 | Jan 18, 2024, 07:47 PM |
| Mates Sharon | Chairman, President & CEO | Jan 16, 2024 | Option Exercise | $16.86 | 75,361 | 1,270,587 | 1,125,670 | Jan 18, 2024, 07:47 PM |
| Mates Sharon | Chairman, President & CEO | Jan 18, 2024 | Option Exercise | $16.86 | 67,917 | 1,145,081 | 1,118,226 | Jan 18, 2024, 07:47 PM |
| Mates Sharon | Chairman, President & CEO | Jan 16, 2024 | Sale | $67.25 | 75,361 | 5,067,982 | 1,122,170 | Jan 18, 2024, 07:47 PM |
| Mates Sharon | Chairman, President & CEO | Jan 18, 2024 | Sale | $65.19 | 67,917 | 4,427,849 | 1,050,629 | Jan 18, 2024, 07:47 PM |
| Mates Sharon | Chairman, President & CEO | Jan 17, 2024 | Sale | $66.24 | 48,084 | 3,185,062 | 1,067,760 | Jan 18, 2024, 07:47 PM |
| Halstead Michael | EVP and General Counsel | Jan 11, 2024 | Option Exercise | $13.60 | 50,000 | 680,051 | 50,000 | Jan 12, 2024, 06:02 PM |
| Halstead Michael | EVP and General Counsel | Jan 11, 2024 | Sale | $66.83 | 50,000 | 3,341,698 | 31,846 | Jan 12, 2024, 06:02 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Jan 02, 2024 | Option Exercise | $19.87 | 62,282 | 1,237,543 | 62,282 | Jan 04, 2024, 07:54 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Jan 02, 2024 | Sale | $70.60 | 62,282 | 4,397,113 | 24,855 | Jan 04, 2024, 07:54 PM |
| RIGGS RORY B | Director | Dec 31, 2023 | Option Exercise | $71.62 | 251 | 17,977 | 79,235 | Jan 03, 2024, 06:46 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 31, 2023 | Option Exercise | $71.62 | 76 | 5,443 | 9,611 | Jan 03, 2024, 06:43 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Dec 13, 2023 | Sale | $65.00 | 21,262 | 1,382,030 | 0 | Dec 15, 2023, 05:01 PM |
| Halstead Michael | EVP and General Counsel | Nov 13, 2023 | Option Exercise | $13.56 | 50,000 | 678,049 | 50,000 | Nov 14, 2023, 05:33 PM |
| Halstead Michael | EVP and General Counsel | Nov 13, 2023 | Sale | $53.90 | 50,000 | 2,694,783 | 41,067 | Nov 14, 2023, 05:33 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Nov 06, 2023 | Option Exercise | $23.94 | 26,754 | 640,491 | 72,093 | Nov 08, 2023, 05:31 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Nov 06, 2023 | Sale | $55.63 | 42,393 | 2,358,152 | 45,339 | Nov 08, 2023, 05:31 PM |
| VAN NOSTRAND ROBERT L | Director | Sep 30, 2023 | Option Exercise | $52.09 | 105 | 5,469 | 9,535 | Oct 02, 2023, 05:30 PM |
| RIGGS RORY B | Director | Sep 30, 2023 | Option Exercise | $52.09 | 345 | 17,971 | 78,984 | Oct 02, 2023, 05:29 PM |
| Mates Sharon | Chairman, President & CEO | Sep 19, 2023 | Sale | $54.17 | 44,413 | 2,405,852 | 1,050,309 | Sep 19, 2023, 08:40 PM |
| Mates Sharon | Chairman, President & CEO | Sep 18, 2023 | Sale | $53.76 | 55,587 | 2,988,213 | 1,122,841 | Sep 19, 2023, 08:40 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Aug 07, 2023 | Option Exercise | $18.59 | 55,300 | 1,028,027 | 100,639 | Aug 09, 2023, 06:05 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Aug 07, 2023 | Sale | $58.79 | 55,300 | 3,251,087 | 45,339 | Aug 09, 2023, 06:05 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Jul 17, 2023 | Sale | $65.00 | 1,842 | 119,730 | 21,262 | Jul 20, 2023, 05:47 PM |
| VAN NOSTRAND ROBERT L | Director | Jun 30, 2023 | Option Exercise | $63.32 | 85 | 5,382 | 9,430 | Jul 05, 2023, 04:29 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jun 14, 2023 | Option Exercise | $42.30 | 81,854 | 3,462,317 | 81,854 | Jun 16, 2023, 05:05 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jun 14, 2023 | Sale | $63.97 | 81,854 | 5,236,329 | 47,627 | Jun 16, 2023, 05:05 PM |
| VAN NOSTRAND ROBERT L | Director | Apr 17, 2023 | Option Exercise | $13.05 | 10,000 | 130,500 | 19,345 | Apr 19, 2023, 06:00 PM |
| VAN NOSTRAND ROBERT L | Director | Apr 17, 2023 | Sale | $63.00 | 10,000 | 630,000 | 9,345 | Apr 19, 2023, 06:00 PM |
| RIGGS RORY B | Director | Mar 31, 2023 | Option Exercise | $54.15 | 313 | 16,949 | 78,360 | Apr 04, 2023, 05:01 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Mar 28, 2023 | Sale | $54.31 | 15,604 | 847,380 | 55,522 | Mar 30, 2023, 05:08 PM |
| Durgam Suresh K. | EVP, Chief Medical Officer | Mar 13, 2023 | Sale | $45.04 | 7,344 | 330,794 | 23,450 | Mar 13, 2023, 07:36 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Mar 13, 2023 | Sale | $44.98 | 3,758 | 169,042 | 61,366 | Mar 13, 2023, 07:35 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Mar 10, 2023 | Sale | $43.34 | 8,550 | 370,557 | 59,157 | Mar 13, 2023, 07:35 PM |
| Halstead Michael | EVP and General Counsel | Mar 10, 2023 | Sale | $43.10 | 16,708 | 720,086 | 2,500 | Mar 13, 2023, 07:34 PM |
| Halstead Michael | EVP and General Counsel | Mar 13, 2023 | Sale | $44.94 | 7,344 | 330,007 | 476 | Mar 13, 2023, 07:34 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Mar 13, 2023 | Sale | $44.93 | 5,582 | 250,808 | 258 | Mar 13, 2023, 07:32 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Mar 10, 2023 | Sale | $43.06 | 15,663 | 674,417 | 2,700 | Mar 13, 2023, 07:32 PM |
| Mates Sharon | Chairman, President & CEO | Mar 13, 2023 | Option Exercise | $3.26 | 20,000 | 65,200 | 1,150,309 | Mar 13, 2023, 07:31 PM |
| Mates Sharon | Chairman, President & CEO | Mar 13, 2023 | Sale | $44.99 | 20,565 | 925,275 | 1,131,721 | Mar 13, 2023, 07:31 PM |
| Mates Sharon | Chairman, President & CEO | Mar 10, 2023 | Sale | $43.15 | 41,770 | 1,802,566 | 1,137,114 | Mar 13, 2023, 07:31 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Mar 01, 2023 | Sale | $50.01 | 7,241 | 362,122 | 49,199 | Mar 03, 2023, 07:03 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Feb 24, 2023 | Sale | $47.12 | 4,046 | 190,648 | 56,440 | Feb 27, 2023, 08:03 PM |
| Durgam Suresh K. | SVP, Chief Medical Officer | Feb 24, 2023 | Sale | $47.14 | 7,906 | 372,689 | 23,104 | Feb 27, 2023, 08:02 PM |
| Halstead Michael | EVP and General Counsel | Feb 24, 2023 | Sale | $47.03 | 7,906 | 371,819 | 0 | Feb 27, 2023, 08:01 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 24, 2023 | Sale | $47.03 | 7,455 | 350,609 | 0 | Feb 27, 2023, 08:00 PM |
| Mates Sharon | Chairman, President & CEO | Feb 24, 2023 | Option Exercise | $3.26 | 30,000 | 97,800 | 1,130,309 | Feb 27, 2023, 07:59 PM |
| Mates Sharon | Chairman, President & CEO | Feb 24, 2023 | Sale | $47.03 | 22,590 | 1,062,408 | 1,100,309 | Feb 27, 2023, 07:59 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Feb 21, 2023 | Sale | $47.01 | 3,898 | 183,246 | 53,338 | Feb 22, 2023, 08:05 PM |
| Durgam Suresh K. | SVP, Chief Medical Officer | Feb 21, 2023 | Sale | $46.84 | 8,354 | 391,304 | 24,785 | Feb 22, 2023, 08:04 PM |
| Halstead Michael | EVP and General Counsel | Feb 21, 2023 | Sale | $46.84 | 11,139 | 521,699 | 1,843 | Feb 22, 2023, 08:03 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 17, 2023 | Option Exercise | $12.73 | 53,968 | 687,013 | 53,968 | Feb 22, 2023, 08:02 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 21, 2023 | Sale | $46.82 | 10,443 | 488,891 | 1,794 | Feb 22, 2023, 08:02 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 17, 2023 | Sale | $49.83 | 53,968 | 2,689,464 | 1,689 | Feb 22, 2023, 08:02 PM |
| Mates Sharon | Chairman, President & CEO | Feb 21, 2023 | Sale | $46.83 | 27,848 | 1,304,000 | 1,105,262 | Feb 22, 2023, 08:01 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 30, 2022 | Option Exercise | $52.92 | 97 | 5,133 | 9,250 | Jan 03, 2023, 04:19 PM |
| RIGGS RORY B | Director | Dec 30, 2022 | Option Exercise | $52.92 | 321 | 16,987 | 78,047 | Jan 03, 2023, 04:18 PM |
| MARCUS JOEL S | Director | Dec 19, 2022 | Sale | $50.82 | 5,000 | 254,100 | 29,233 | Dec 21, 2022, 04:06 PM |
| Mates Sharon | Chairman, President & CEO | Dec 13, 2022 | Sale | $55.00 | 33,083 | 1,819,565 | 1,100,309 | Dec 15, 2022, 07:01 PM |
| Halstead Michael | EVP and General Counsel | Dec 01, 2022 | Option Exercise | $15.47 | 50,000 | 773,500 | 50,000 | Dec 02, 2022, 07:14 PM |
| Halstead Michael | EVP and General Counsel | Dec 01, 2022 | Sale | $53.73 | 50,000 | 2,686,514 | 22,796 | Dec 02, 2022, 07:14 PM |
| MARCUS JOEL S | Director | Nov 07, 2022 | Sale | $52.30 | 10,000 | 523,023 | 39,233 | Nov 08, 2022, 04:12 PM |
| VAN NOSTRAND ROBERT L | Director | Sep 30, 2022 | Option Exercise | $46.53 | 110 | 5,118 | 9,153 | Oct 05, 2022, 04:04 PM |
| RIGGS RORY B | Director | Sep 30, 2022 | Option Exercise | $46.53 | 365 | 16,983 | 77,726 | Oct 04, 2022, 04:11 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Sep 21, 2022 | Option Exercise | $15.47 | 65,164 | 1,008,087 | 65,164 | Sep 23, 2022, 09:01 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Sep 21, 2022 | Sale | $45.63 | 65,164 | 2,973,406 | 33,303 | Sep 23, 2022, 09:01 PM |
| VAN NOSTRAND ROBERT L | Director | Aug 11, 2022 | Option Exercise | $12.65 | 30,000 | 379,500 | 39,043 | Aug 12, 2022, 06:09 PM |
| VAN NOSTRAND ROBERT L | Director | Aug 11, 2022 | Sale | $57.13 | 30,000 | 1,713,975 | 10,543 | Aug 12, 2022, 06:09 PM |
| MARCUS JOEL S | Director | Aug 11, 2022 | Sale | $59.22 | 10,000 | 592,200 | 44,233 | Aug 12, 2022, 06:05 PM |
| RIGGS RORY B | Director | Jun 30, 2022 | Option Exercise | $57.08 | 289 | 16,496 | 77,361 | Jul 05, 2022, 04:06 PM |
| MARCUS JOEL S | Director | May 12, 2022 | Sale | $55.00 | 10,000 | 550,000 | 54,233 | May 13, 2022, 05:24 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Apr 08, 2022 | Option Exercise | $12.73 | 86,348 | 1,099,210 | 131,687 | Apr 08, 2022, 06:56 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Apr 08, 2022 | Sale | $64.37 | 86,348 | 5,558,051 | 114,211 | Apr 08, 2022, 06:56 PM |
| VAN NOSTRAND ROBERT L | Director | Mar 31, 2022 | Option Exercise | $61.19 | 126 | 7,710 | 8,935 | Apr 04, 2022, 04:11 PM |
| RIGGS RORY B | Director | Mar 31, 2022 | Option Exercise | $61.19 | 257 | 15,726 | 77,072 | Apr 04, 2022, 04:08 PM |
| RIGGS RORY B | Director | Mar 18, 2022 | Sale | $61.18 | 20,637 | 1,262,505 | 15,736 | Mar 18, 2022, 08:12 PM |
| RIGGS RORY B | Director | Mar 17, 2022 | Sale | $60.33 | 141,499 | 8,536,646 | 135,549 | Mar 18, 2022, 08:12 PM |
| RIGGS RORY B | Director | Mar 16, 2022 | Sale | $59.27 | 64,534 | 3,824,827 | 205,984 | Mar 18, 2022, 08:12 PM |
| Mates Sharon | Chairman, President & CEO | Mar 09, 2022 | Option Exercise | $2.84 | 38,925 | 110,547 | 1,133,392 | Mar 10, 2022, 04:13 PM |
| MARCUS JOEL S | Director | Mar 08, 2022 | Sale | $52.68 | 15,000 | 790,150 | 38,980 | Mar 09, 2022, 09:49 PM |
| MARCUS JOEL S | Director | Mar 07, 2022 | Sale | $54.52 | 5,000 | 272,600 | 43,980 | Mar 09, 2022, 09:49 PM |
| Durgam Suresh K. | Chief Medical Officer | Mar 04, 2022 | Sale | $55.52 | 3,860 | 214,307 | 23,104 | Mar 04, 2022, 06:05 PM |
| Durgam Suresh K. | Chief Medical Officer | Mar 02, 2022 | Sale | $56.98 | 4,177 | 238,005 | 26,964 | Mar 04, 2022, 06:05 PM |
| Durgam Suresh K. | Chief Medical Officer | Feb 24, 2022 | Sale | $52.27 | 4,046 | 211,468 | 33,984 | Feb 25, 2022, 07:09 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Feb 24, 2022 | Sale | $52.21 | 7,906 | 412,810 | 50,585 | Feb 25, 2022, 07:08 PM |
| Halstead Michael | EVP and General Counsel | Feb 24, 2022 | Sale | $51.98 | 7,906 | 410,933 | 4,188 | Feb 25, 2022, 07:06 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 24, 2022 | Sale | $51.97 | 7,454 | 387,349 | 4,083 | Feb 25, 2022, 07:04 PM |
| Mates Sharon | Chairman, President & CEO | Feb 24, 2022 | Sale | $51.98 | 22,589 | 1,174,074 | 1,105,807 | Feb 25, 2022, 07:01 PM |
| Durgam Suresh K. | Chief Medical Officer | Feb 22, 2022 | Sale | $55.29 | 4,177 | 230,958 | 28,638 | Feb 23, 2022, 07:08 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Feb 22, 2022 | Sale | $55.29 | 11,139 | 615,827 | 49,946 | Feb 23, 2022, 07:07 PM |
| Halstead Michael | EVP and General Counsel | Feb 22, 2022 | Sale | $55.40 | 11,139 | 617,100 | 4,550 | Feb 23, 2022, 07:05 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 22, 2022 | Sale | $55.40 | 10,443 | 578,506 | 4,627 | Feb 23, 2022, 07:02 PM |
| Mates Sharon | Chairman, President & CEO | Feb 22, 2022 | Sale | $55.39 | 27,847 | 1,542,413 | 1,107,134 | Feb 23, 2022, 07:00 PM |
| Durgam Suresh K. | Chief Medical Officer | Jan 18, 2022 | Sale | $42.03 | 6,223 | 261,553 | 23,104 | Jan 20, 2022, 04:07 PM |
| Durgam Suresh K. | Chief Medical Officer | Jan 10, 2022 | Sale | $40.76 | 6,870 | 280,020 | 34,677 | Jan 11, 2022, 08:08 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Jan 10, 2022 | Sale | $40.78 | 20,948 | 854,255 | 63,526 | Jan 11, 2022, 08:06 PM |
| Halstead Michael | EVP and General Counsel | Jan 10, 2022 | Sale | $40.77 | 19,639 | 800,774 | 17,135 | Jan 11, 2022, 08:04 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 10, 2022 | Sale | $40.76 | 19,639 | 800,420 | 16,534 | Jan 11, 2022, 08:02 PM |
| Mates Sharon | Chairman, President & CEO | Jan 10, 2022 | Sale | $40.78 | 41,896 | 1,708,429 | 1,130,559 | Jan 11, 2022, 08:00 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 31, 2021 | Option Exercise | $52.34 | 148 | 7,746 | 8,809 | Jan 04, 2022, 09:52 PM |
| RIGGS RORY B | Director | Dec 31, 2021 | Option Exercise | $52.34 | 300 | 15,702 | 76,815 | Jan 04, 2022, 09:50 PM |
| Halstead Michael | EVP and General Counsel | Dec 21, 2021 | Option Exercise | $16.38 | 176,863 | 2,897,494 | 176,863 | Dec 23, 2021, 07:02 PM |
| Halstead Michael | EVP and General Counsel | Dec 21, 2021 | Sale | $47.56 | 176,863 | 8,412,278 | 154,243 | Dec 23, 2021, 07:02 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Dec 21, 2021 | Option Exercise | $16.81 | 175,000 | 2,941,951 | 175,000 | Dec 23, 2021, 07:00 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Dec 21, 2021 | Sale | $47.59 | 175,000 | 8,328,664 | 149,538 | Dec 23, 2021, 07:00 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Oct 18, 2021 | Sale | $40.86 | 13,448 | 549,551 | 52,085 | Oct 19, 2021, 04:26 PM |
| Mates Sharon | Chairman, President & CEO | Oct 15, 2021 | Option Exercise | $2.84 | 1,075 | 3,053 | 1,102,659 | Oct 18, 2021, 06:00 PM |
| Mates Sharon | Chairman, President & CEO | Oct 18, 2021 | Sale | $40.00 | 8,192 | 327,680 | 1,094,467 | Oct 18, 2021, 06:00 PM |
| Mates Sharon | Chairman, President & CEO | Oct 15, 2021 | Sale | $40.00 | 40,392 | 1,615,680 | 1,101,584 | Oct 18, 2021, 06:00 PM |
| Mates Sharon | Chairman, President & CEO | Oct 14, 2021 | Sale | $40.00 | 1,416 | 56,640 | 1,141,976 | Oct 18, 2021, 06:00 PM |
| LERNER RICHARD A | Director | Sep 30, 2021 | Option Exercise | $37.28 | 402 | 14,987 | 96,663 | Oct 04, 2021, 05:43 PM |
| RIGGS RORY B | Director | Sep 30, 2021 | Option Exercise | $37.28 | 422 | 15,732 | 76,515 | Oct 04, 2021, 04:24 PM |
| VAN NOSTRAND ROBERT L | Director | Sep 30, 2021 | Option Exercise | $37.28 | 215 | 8,015 | 8,661 | Oct 04, 2021, 04:23 PM |
| Mates Sharon | Chairman, President & CEO | Aug 23, 2021 | Option Exercise | $2.84 | 10,000 | 28,400 | 1,143,392 | Aug 24, 2021, 04:06 PM |
| VAN NOSTRAND ROBERT L | Director | Jun 30, 2021 | Option Exercise | $40.82 | 173 | 7,062 | 8,446 | Jul 02, 2021, 04:55 PM |
| RIGGS RORY B | Director | Jun 30, 2021 | Option Exercise | $40.82 | 385 | 15,716 | 76,093 | Jul 02, 2021, 04:52 PM |
| LERNER RICHARD A | Director | Jun 30, 2021 | Option Exercise | $40.82 | 367 | 14,981 | 96,261 | Jul 02, 2021, 04:47 PM |
| Alafi Christopher D | Director | May 24, 2021 | Sale | $40.47 | 26,575 | 1,075,490 | 142,325 | May 25, 2021, 06:02 PM |
| Alafi Christopher D | Director | May 21, 2021 | Sale | $40.00 | 1,100 | 44,000 | 168,900 | May 25, 2021, 06:02 PM |
| LERNER RICHARD A | Director | Mar 31, 2021 | Option Exercise | $33.93 | 442 | 14,997 | 95,894 | Apr 02, 2021, 05:31 PM |
| MARCUS JOEL S | Director | Mar 02, 2021 | Option Exercise | $26.58 | 20,000 | 531,600 | 87,519 | Mar 04, 2021, 05:43 PM |
| MARCUS JOEL S | Director | Mar 02, 2021 | Sale | $34.93 | 15,250 | 532,683 | 72,269 | Mar 04, 2021, 05:43 PM |
| Durgam Suresh K. | Chief Medical Officer | Feb 19, 2021 | Sale | $39.25 | 2,734 | 107,310 | 23,304 | Feb 22, 2021, 08:09 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Feb 19, 2021 | Sale | $39.22 | 5,184 | 203,308 | 45,939 | Feb 22, 2021, 08:07 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 19, 2021 | Sale | $39.23 | 10,442 | 409,625 | 1,200 | Feb 22, 2021, 08:05 PM |
| Halstead Michael | EVP and General Counsel | Feb 19, 2021 | Sale | $39.24 | 11,139 | 437,133 | 1,100 | Feb 22, 2021, 08:03 PM |
| Mates Sharon | Chairman, President & CEO | Feb 19, 2021 | Sale | $39.23 | 27,847 | 1,092,436 | 1,136,492 | Feb 22, 2021, 08:01 PM |
| Durgam Suresh K. | Chief Medical Officer | Jan 11, 2021 | Sale | $32.12 | 4,367 | 140,259 | 17,584 | Jan 12, 2021, 07:07 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Jan 11, 2021 | Sale | $32.02 | 9,684 | 310,082 | 39,384 | Jan 12, 2021, 07:06 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 11, 2021 | Sale | $32.02 | 19,638 | 628,769 | 2,376 | Jan 12, 2021, 07:05 PM |
| Halstead Michael | EVP and General Counsel | Jan 11, 2021 | Sale | $32.03 | 19,638 | 628,978 | 1,936 | Jan 12, 2021, 07:03 PM |
| Mates Sharon | Chairman, President & CEO | Jan 11, 2021 | Sale | $32.01 | 41,896 | 1,341,260 | 1,137,977 | Jan 12, 2021, 07:01 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 04, 2021 | Sale | $31.31 | 15,810 | 495,008 | 3,450 | Jan 05, 2021, 06:13 PM |
| Halstead Michael | EVP and General Counsel | Jan 04, 2021 | Sale | $31.30 | 16,160 | 505,834 | 3,174 | Jan 05, 2021, 06:11 PM |
| Mates Sharon | Chairman, President & CEO | Jan 04, 2021 | Sale | $31.30 | 48,341 | 1,513,271 | 1,153,820 | Jan 05, 2021, 06:09 PM |
| LERNER RICHARD A | Director | Dec 31, 2020 | Option Exercise | $31.80 | 471 | 14,978 | 95,452 | Jan 05, 2021, 06:07 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 31, 2020 | Option Exercise | $31.80 | 222 | 7,060 | 8,065 | Jan 05, 2021, 06:05 PM |
| RIGGS RORY B | Director | Dec 31, 2020 | Option Exercise | $31.80 | 495 | 15,741 | 61,477 | Jan 05, 2021, 06:03 PM |
| Alafi Christopher D | Director | Dec 31, 2020 | Option Exercise | $31.80 | 495 | 15,741 | 346,331 | Jan 05, 2021, 06:01 PM |
| Mates Sharon | Chairman, President & CEO | Dec 18, 2020 | Option Exercise | $2.74 | 34,000 | 93,160 | 1,147,392 | Dec 21, 2020, 04:03 PM |
| Halstead Michael | EVP and General Counsel | Nov 17, 2020 | Option Exercise | $13.86 | 75,000 | 1,039,500 | 79,425 | Nov 19, 2020, 08:05 PM |
| Halstead Michael | EVP and General Counsel | Nov 17, 2020 | Sale | $27.62 | 79,425 | 2,193,446 | 3,761 | Nov 19, 2020, 08:05 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Nov 11, 2020 | Option Exercise | $3.05 | 20,000 | 61,000 | 28,034 | Nov 13, 2020, 05:51 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Nov 11, 2020 | Sale | $25.41 | 28,034 | 712,344 | 0 | Nov 13, 2020, 05:51 PM |
| Mates Sharon | Chairman, President & CEO | Nov 10, 2020 | Sale | $26.34 | 50,000 | 1,317,101 | 1,132,523 | Nov 12, 2020, 05:51 PM |
| Mates Sharon | Chairman, President & CEO | Nov 04, 2020 | Sale | $25.00 | 50,000 | 1,250,000 | 1,163,392 | Nov 06, 2020, 06:00 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Oct 16, 2020 | Sale | $26.80 | 6,792 | 182,026 | 28,120 | Oct 16, 2020, 04:04 PM |
| VAN NOSTRAND ROBERT L | Director | Sep 30, 2020 | Option Exercise | $25.66 | 276 | 7,082 | 7,843 | Oct 02, 2020, 04:24 PM |
| RIGGS RORY B | Director | Sep 30, 2020 | Option Exercise | $25.66 | 613 | 15,730 | 60,982 | Oct 02, 2020, 04:22 PM |
| LERNER RICHARD A | Director | Sep 30, 2020 | Option Exercise | $25.66 | 584 | 14,985 | 94,981 | Oct 02, 2020, 04:17 PM |
| Alafi Christopher D | Director | Sep 30, 2020 | Option Exercise | $25.66 | 613 | 15,730 | 345,836 | Oct 02, 2020, 04:13 PM |
| Alafi Christopher D | Director | Sep 14, 2020 | Buy | $29.60 | 49,500 | 1,465,200 | 4,743,770 | Sep 14, 2020, 05:03 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Sep 09, 2020 | Option Exercise | $12.73 | 26,983 | 343,494 | 50,017 | Sep 11, 2020, 07:08 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Sep 09, 2020 | Sale | $31.14 | 41,983 | 1,307,351 | 8,034 | Sep 11, 2020, 07:08 PM |
| Alafi Christopher D | Director | Sep 11, 2020 | Buy | $28.08 | 21,000 | 589,680 | 4,694,270 | Sep 11, 2020, 04:15 PM |
| VAN NOSTRAND ROBERT L | Director | Jun 30, 2020 | Option Exercise | $25.67 | 275 | 7,059 | 7,567 | Jul 02, 2020, 07:12 PM |
| LERNER RICHARD A | Director | Jun 30, 2020 | Option Exercise | $25.67 | 584 | 14,991 | 94,397 | Jul 02, 2020, 07:05 PM |
| RIGGS RORY B | Director | Jun 30, 2020 | Option Exercise | $25.67 | 613 | 15,736 | 60,369 | Jul 02, 2020, 07:02 PM |
| Alafi Christopher D | Director | Jun 30, 2020 | Option Exercise | $25.67 | 613 | 15,736 | 345,223 | Jul 02, 2020, 06:58 PM |
| MARCUS JOEL S | Director | May 14, 2020 | Sale | $20.04 | 9,602 | 192,424 | 39,140 | May 15, 2020, 05:37 PM |
| MARCUS JOEL S | Director | May 11, 2020 | Sale | $19.95 | 50,000 | 997,500 | 48,742 | May 13, 2020, 07:48 PM |
| MARCUS JOEL S | Director | May 13, 2020 | Sale | $20.63 | 7,297 | 150,537 | 14,374 | May 13, 2020, 07:48 PM |
| LERNER RICHARD A | Director | May 11, 2020 | Option Exercise | $2.74 | 25,000 | 68,500 | 97,313 | May 13, 2020, 05:20 PM |
| LERNER RICHARD A | Director | May 11, 2020 | Sale | $20.50 | 3,500 | 71,750 | 93,813 | May 13, 2020, 05:20 PM |
| Alafi Christopher D | Director | Mar 31, 2020 | Option Exercise | $15.37 | 1,024 | 15,739 | 344,610 | Apr 02, 2020, 06:05 PM |
| LERNER RICHARD A | Director | Mar 31, 2020 | Option Exercise | $15.37 | 975 | 14,986 | 72,313 | Apr 02, 2020, 06:01 PM |
| VAN NOSTRAND ROBERT L | Director | Mar 31, 2020 | Option Exercise | $15.37 | 460 | 7,070 | 7,292 | Apr 02, 2020, 05:55 PM |
| RIGGS RORY B | Director | Mar 31, 2020 | Option Exercise | $15.37 | 1,024 | 15,739 | 45,751 | Apr 02, 2020, 05:50 PM |
| Halstead Michael | EVP and General Counsel | Jan 24, 2020 | Option Exercise | $23.61 | 3,809 | 89,930 | 4,425 | Jan 28, 2020, 09:31 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 24, 2020 | Option Exercise | $23.61 | 3,809 | 89,930 | 23,034 | Jan 28, 2020, 09:30 PM |
| Mates Sharon | Chairman, President & CEO | Jan 24, 2020 | Option Exercise | $23.61 | 9,323 | 220,116 | 1,213,392 | Jan 28, 2020, 09:28 PM |
| LERNER RICHARD A | Director | Dec 31, 2019 | Option Exercise | $34.31 | 400 | 13,724 | 71,338 | Jan 16, 2020, 06:13 PM |
| Satlin Andrew | EVP and Chief Medical Officer | Jan 09, 2020 | Sale | $26.16 | 11,573 | 302,750 | 11,338 | Jan 10, 2020, 09:14 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Jan 08, 2020 | Option Exercise | $26.34 | 6,157 | 162,175 | 21,464 | Jan 10, 2020, 09:11 PM |
| Mates Sharon | Chairman, President & CEO | Jan 09, 2020 | Sale | $26.16 | 41,895 | 1,095,973 | 1,204,707 | Jan 10, 2020, 09:09 PM |
| Halstead Michael | EVP and General Counsel | Jan 09, 2020 | Sale | $26.16 | 19,638 | 513,730 | 191 | Jan 10, 2020, 09:06 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 09, 2020 | Sale | $26.16 | 19,638 | 513,730 | 18,800 | Jan 10, 2020, 09:03 PM |
| Mates Sharon | Chairman, President & CEO | Jan 08, 2020 | Option Exercise | $2.74 | 60,000 | 164,400 | 1,246,602 | Jan 08, 2020, 09:11 PM |
| Mates Sharon | Chairman, President & CEO | Jan 06, 2020 | Sale | $30.28 | 45,598 | 1,380,880 | 1,182,366 | Jan 08, 2020, 09:11 PM |
| Halstead Michael | EVP and General Counsel | Jan 06, 2020 | Sale | $30.34 | 21,458 | 651,007 | 17,704 | Jan 08, 2020, 09:02 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 06, 2020 | Sale | $30.29 | 21,458 | 650,003 | 36,391 | Jan 08, 2020, 09:00 PM |
| Halstead Michael | EVP and General Counsel | Jan 02, 2020 | Sale | $32.43 | 7,807 | 253,214 | 6,375 | Jan 03, 2020, 09:17 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 02, 2020 | Sale | $32.43 | 7,807 | 253,165 | 25,807 | Jan 03, 2020, 09:16 PM |
| Mates Sharon | Chairman, President & CEO | Dec 31, 2019 | Option Exercise | $2.74 | 6,000 | 16,440 | 1,162,185 | Jan 03, 2020, 09:14 PM |
| Mates Sharon | Chairman, President & CEO | Jan 02, 2020 | Sale | $32.45 | 17,478 | 567,230 | 1,158,485 | Jan 03, 2020, 09:14 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 31, 2019 | Option Exercise | $34.31 | 170 | 5,833 | 6,832 | Jan 03, 2020, 09:13 PM |
| RIGGS RORY B | Director | Dec 31, 2019 | Option Exercise | $34.31 | 422 | 14,479 | 44,727 | Jan 03, 2020, 09:12 PM |
| Alafi Christopher D | Director | Dec 31, 2019 | Option Exercise | $34.31 | 422 | 14,479 | 343,586 | Jan 03, 2020, 09:11 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Dec 23, 2019 | Option Exercise | $2.74 | 9,600 | 26,304 | 34,832 | Dec 26, 2019, 04:06 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Dec 23, 2019 | Sale | $25.50 | 15,032 | 383,316 | 25,232 | Dec 26, 2019, 04:06 PM |
| Neumann Mark | EVP, Chief Commercial Officer | Oct 16, 2019 | Sale | $8.25 | 6,774 | 55,886 | 6,674 | Oct 17, 2019, 04:50 PM |
| RIGGS RORY B | Director | Sep 30, 2019 | Option Exercise | $7.47 | 1,941 | 14,499 | 44,305 | Oct 02, 2019, 05:37 PM |
| LERNER RICHARD A | Director | Sep 30, 2019 | Option Exercise | $7.47 | 1,840 | 13,745 | 70,938 | Oct 02, 2019, 05:35 PM |
| VAN NOSTRAND ROBERT L | Director | Sep 30, 2019 | Option Exercise | $7.47 | 780 | 5,827 | 6,662 | Oct 02, 2019, 05:32 PM |
| Alafi Christopher D | Director | Sep 30, 2019 | Option Exercise | $7.47 | 1,941 | 14,499 | 343,164 | Oct 02, 2019, 05:29 PM |
| Alafi Christopher D | Director | Sep 10, 2019 | Buy | $10.26 | 485,000 | 4,974,678 | 4,673,270 | Sep 11, 2019, 04:30 PM |
| Alafi Christopher D | Director | Aug 30, 2019 | Buy | $8.52 | 125,000 | 1,065,212 | 4,188,270 | Sep 04, 2019, 06:24 PM |
| VAN NOSTRAND ROBERT L | Director | Jun 28, 2019 | Option Exercise | $12.98 | 449 | 5,828 | 5,882 | Jul 02, 2019, 05:17 PM |
| LERNER RICHARD A | Director | Jun 28, 2019 | Option Exercise | $12.98 | 1,059 | 13,746 | 69,098 | Jul 02, 2019, 05:12 PM |
| RIGGS RORY B | Director | Jun 28, 2019 | Option Exercise | $12.98 | 1,117 | 14,499 | 42,364 | Jul 02, 2019, 05:03 PM |
| Alafi Christopher D | Director | Jun 28, 2019 | Option Exercise | $12.98 | 1,117 | 14,499 | 341,223 | Jul 02, 2019, 12:00 AM |
| Alafi Christopher D | Director | Nov 22, 2017 | Buy | $15.55 | 10,000 | 155,500 | 3,963,270 | Jun 19, 2019, 05:48 PM |
| Alafi Christopher D | Director | Jun 12, 2019 | Buy | $11.73 | 170,000 | 1,993,793 | 170,000 | Jun 14, 2019, 05:23 PM |
| MARCUS JOEL S | Director | May 29, 2019 | Option Exercise | $12.45 | 20,000 | 249,000 | 41,671 | May 31, 2019, 04:35 PM |
| Alafi Christopher D | Director | May 14, 2019 | Buy | $12.56 | 100,000 | 1,256,350 | 4,053,270 | May 15, 2019, 06:03 PM |
| Alafi Christopher D | Director | Mar 31, 2019 | Option Exercise | $12.18 | 1,190 | 14,494 | 750,106 | Apr 02, 2019, 07:03 PM |
| VAN NOSTRAND ROBERT L | Director | Mar 31, 2019 | Option Exercise | $12.18 | 478 | 5,822 | 5,433 | Apr 02, 2019, 06:59 PM |
| RIGGS RORY B | Director | Mar 31, 2019 | Option Exercise | $12.18 | 1,190 | 14,494 | 41,247 | Apr 02, 2019, 06:56 PM |
| LERNER RICHARD A | Director | Mar 31, 2019 | Option Exercise | $12.18 | 1,128 | 13,739 | 68,039 | Apr 02, 2019, 06:52 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 27, 2019 | Option Exercise | $2.74 | 10,400 | 28,496 | 26,232 | Mar 01, 2019, 07:41 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Feb 27, 2019 | Sale | $15.00 | 1,000 | 15,000 | 25,232 | Mar 01, 2019, 07:41 PM |
| Mates Sharon | Chairman, President & CEO | Jan 07, 2019 | Sale | $12.43 | 6,604 | 82,088 | 1,138,707 | Jan 08, 2019, 09:28 PM |
| Mates Sharon | Chairman, President & CEO | Jan 04, 2019 | Sale | $11.45 | 45,598 | 522,222 | 1,152,850 | Jan 08, 2019, 09:28 PM |
| Halstead Michael | EVP and General Counsel | Jan 07, 2019 | Sale | $12.42 | 3,108 | 38,601 | 191 | Jan 08, 2019, 09:24 PM |
| Halstead Michael | EVP and General Counsel | Jan 04, 2019 | Sale | $11.46 | 21,458 | 245,817 | 8,697 | Jan 08, 2019, 09:24 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 07, 2019 | Sale | $12.42 | 3,108 | 38,601 | 17,032 | Jan 08, 2019, 09:21 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 04, 2019 | Sale | $11.45 | 21,458 | 245,782 | 21,882 | Jan 08, 2019, 09:21 PM |
| Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 07, 2019 | Sale | $12.29 | 592 | 7,276 | 27,068 | Jan 08, 2019, 09:19 PM |
| Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 04, 2019 | Sale | $11.47 | 9,564 | 109,704 | 29,844 | Jan 08, 2019, 09:19 PM |
| Davis Robert E | SVP, Chief Scientific Officer | Jan 04, 2019 | Sale | $11.46 | 9,564 | 109,630 | 46,691 | Jan 08, 2019, 09:16 PM |
| Mates Sharon | Chairman, President & CEO | Jan 02, 2019 | Sale | $11.09 | 17,478 | 193,831 | 1,138,707 | Jan 03, 2019, 09:02 PM |
| Halstead Michael | EVP and General Counsel | Jan 02, 2019 | Sale | $11.09 | 7,807 | 86,580 | 191 | Jan 03, 2019, 08:58 PM |
| Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 02, 2019 | Sale | $11.10 | 4,834 | 53,657 | 16,861 | Jan 03, 2019, 08:46 PM |
| Davis Robert E | SVP, Chief Scientific Officer | Jan 02, 2019 | Sale | $11.11 | 4,834 | 53,706 | 34,744 | Jan 03, 2019, 08:42 PM |
| Hineline Lawrence J. | SVP of Finance CFO | Jan 02, 2019 | Sale | $11.09 | 7,807 | 86,580 | 17,032 | Jan 03, 2019, 08:23 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 31, 2018 | Option Exercise | $11.39 | 512 | 5,832 | 4,955 | Jan 03, 2019, 08:19 PM |
| RIGGS RORY B | Director | Dec 31, 2018 | Option Exercise | $11.39 | 1,273 | 14,499 | 40,057 | Jan 03, 2019, 08:15 PM |
| LERNER RICHARD A | Director | Dec 31, 2018 | Option Exercise | $11.39 | 1,207 | 13,748 | 11,430 | Jan 03, 2019, 08:11 PM |
| Alafi Christopher D | Director | Dec 31, 2018 | Option Exercise | $11.39 | 1,273 | 14,499 | 748,916 | Jan 03, 2019, 08:05 PM |
| Mates Sharon | Chairman, President & CEO | Dec 10, 2018 | Option Exercise | $1.50 | 50,000 | 75,000 | 1,138,707 | Dec 11, 2018, 05:55 PM |
| Davis Robert E | SVP, Chief Scientific Officer | Dec 06, 2018 | Sale | $13.53 | 899 | 12,163 | 30,256 | Dec 07, 2018, 04:44 PM |
| MARCUS JOEL S | Director | Nov 12, 2018 | Sale | $17.94 | 7,000 | 125,580 | 78,742 | Nov 13, 2018, 05:34 PM |
| MARCUS JOEL S | Director | Nov 09, 2018 | Sale | $18.24 | 25,000 | 456,000 | 85,742 | Nov 13, 2018, 05:34 PM |
| LERNER RICHARD A | Director | Oct 22, 2018 | Option Exercise | $1.50 | 12,500 | 18,750 | 66,911 | Oct 24, 2018, 04:33 PM |
| LERNER RICHARD A | Director | Sep 30, 2018 | Option Exercise | $21.70 | 633 | 13,736 | 54,411 | Oct 02, 2018, 08:11 PM |
| RIGGS RORY B | Director | Sep 30, 2018 | Option Exercise | $21.70 | 668 | 14,496 | 38,784 | Oct 02, 2018, 08:08 PM |
| VAN NOSTRAND ROBERT L | Director | Sep 30, 2018 | Option Exercise | $21.70 | 268 | 5,816 | 4,443 | Oct 02, 2018, 08:06 PM |
| Alafi Christopher D | Director | Sep 30, 2018 | Option Exercise | $21.70 | 668 | 14,496 | 747,643 | Oct 02, 2018, 08:01 PM |
| LERNER RICHARD A | Director | Jun 29, 2018 | Option Exercise | $17.67 | 778 | 13,747 | 53,778 | Jul 03, 2018, 04:27 PM |
| Alafi Christopher D | Director | Jun 29, 2018 | Option Exercise | $17.67 | 820 | 14,489 | 746,975 | Jul 03, 2018, 12:00 AM |
| VAN NOSTRAND ROBERT L | Director | Jun 29, 2018 | Option Exercise | $17.67 | 282 | 4,983 | 4,175 | Jul 03, 2018, 12:00 AM |
| RIGGS RORY B | Director | Jun 29, 2018 | Option Exercise | $17.67 | 820 | 14,489 | 38,116 | Jul 03, 2018, 12:00 AM |
| VAN NOSTRAND ROBERT L | Director | Mar 30, 2018 | Option Exercise | $21.05 | 237 | 4,989 | 3,893 | Apr 03, 2018, 04:19 PM |
| Alafi Christopher D | Director | Mar 30, 2018 | Option Exercise | $21.05 | 688 | 14,482 | 746,155 | Apr 03, 2018, 12:00 AM |
| RIGGS RORY B | Director | Mar 30, 2018 | Option Exercise | $21.05 | 688 | 14,482 | 37,296 | Apr 03, 2018, 12:00 AM |
| LERNER RICHARD A | Director | Mar 30, 2018 | Option Exercise | $21.05 | 653 | 13,746 | 10,223 | Apr 03, 2018, 12:00 AM |
| Hineline Lawrence J. | VP of Finance CFO | Feb 16, 2018 | Sale | $20.01 | 16,319 | 326,543 | 17,032 | Feb 20, 2018, 04:38 PM |
| Hineline Lawrence J. | VP of Finance CFO | Feb 15, 2018 | Sale | $20.03 | 33,381 | 668,621 | 33,351 | Feb 20, 2018, 04:38 PM |
| Halstead Michael | SVP and General Counsel | Jan 22, 2018 | Sale | $18.03 | 25,500 | 459,765 | 191 | Jan 24, 2018, 07:11 PM |
| Vanover Kimberly E. | SVP, Clinical Development | Jan 08, 2018 | Sale | $17.46 | 772 | 13,479 | 12,373 | Jan 10, 2018, 09:05 PM |
| Mates Sharon | Chairman, President & CEO | Jan 08, 2018 | Sale | $17.48 | 6,604 | 115,438 | 1,088,707 | Jan 10, 2018, 09:01 PM |
| Mates Sharon | Chairman, President & CEO | Jan 05, 2018 | Sale | $17.08 | 11,257 | 192,270 | 1,095,311 | Jan 05, 2018, 08:19 PM |
| Vanover Kimberly E. | SVP, Clinical Development | Jan 05, 2018 | Sale | $17.37 | 1,185 | 20,583 | 13,145 | Jan 05, 2018, 08:14 PM |
| Davis Robert E | SVP, Chief Scientific Officer | Jan 04, 2018 | Sale | $15.60 | 1,115 | 17,394 | 29,397 | Jan 05, 2018, 08:09 PM |
| Hineline Lawrence J. | VP of Finance CFO | Jan 05, 2018 | Sale | $17.49 | 1,870 | 32,706 | 66,732 | Jan 05, 2018, 08:06 PM |
| Hineline Lawrence J. | VP of Finance CFO | Jan 04, 2018 | Sale | $15.67 | 3,192 | 50,019 | 68,602 | Jan 05, 2018, 08:06 PM |
| Halstead Michael | SVP and General Counsel | Jan 05, 2018 | Sale | $17.49 | 1,560 | 27,284 | 25,691 | Jan 05, 2018, 08:03 PM |
| Halstead Michael | SVP and General Counsel | Jan 04, 2018 | Sale | $15.75 | 2,660 | 41,895 | 27,251 | Jan 05, 2018, 08:03 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 29, 2017 | Option Exercise | $14.48 | 345 | 4,996 | 3,656 | Jan 03, 2018, 06:10 PM |
| RIGGS RORY B | Director | Dec 29, 2017 | Option Exercise | $14.48 | 1,001 | 14,494 | 36,608 | Jan 03, 2018, 06:05 PM |
| LERNER RICHARD A | Director | Dec 29, 2017 | Option Exercise | $14.48 | 949 | 13,742 | 9,570 | Jan 03, 2018, 06:01 PM |
| Alafi Christopher D | Director | Dec 29, 2017 | Option Exercise | $14.48 | 1,001 | 14,494 | 745,467 | Jan 03, 2018, 05:59 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 29, 2017 | Buy | $14.48 | 345 | 4,996 | 3,656 | Jan 03, 2018, 04:31 PM |
| LERNER RICHARD A | Director | Dec 29, 2017 | Buy | $14.48 | 949 | 13,742 | 9,570 | Jan 03, 2018, 04:29 PM |
| RIGGS RORY B | Director | Dec 29, 2017 | Buy | $14.48 | 1,001 | 14,494 | 36,608 | Jan 03, 2018, 12:00 AM |
| Alafi Christopher D | Director | Dec 29, 2017 | Buy | $14.48 | 1,001 | 14,494 | 745,467 | Jan 03, 2018, 12:00 AM |
| LERNER RICHARD A | Director | Dec 11, 2017 | Option Exercise | $1.50 | 12,500 | 18,750 | 60,000 | Dec 13, 2017, 04:52 PM |
| LERNER RICHARD A | Director | Dec 11, 2017 | Sale | $15.09 | 7,000 | 105,630 | 53,000 | Dec 13, 2017, 04:52 PM |
| Davis Robert E | SVP, Chief Scientific Officer | Dec 05, 2017 | Sale | $15.00 | 650 | 9,750 | 27,864 | Dec 06, 2017, 06:33 PM |
| Alafi Christopher D | Director | Nov 22, 2017 | Buy | $15.55 | 10,000 | 155,500 | 744,466 | Nov 27, 2017, 04:31 PM |
| Mates Sharon | Chairman, President & CEO | Oct 30, 2017 | Option Exercise | $1.50 | 18,750 | 28,125 | 1,107,457 | Nov 01, 2017, 08:04 PM |
| Mates Sharon | Chairman, President & CEO | Oct 30, 2017 | Sale | $15.75 | 18,750 | 295,313 | 1,088,707 | Nov 01, 2017, 08:04 PM |
| ALAFI MOSHE | 10% Owner | Oct 02, 2017 | Buy | $15.50 | 258,065 | 4,000,008 | 3,953,270 | Oct 03, 2017, 06:11 PM |
| Alafi Christopher D | Director | Oct 02, 2017 | Buy | $15.50 | 258,065 | 4,000,008 | 3,953,270 | Oct 03, 2017, 06:10 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Oct 02, 2017 | Buy | $15.50 | 258,065 | 4,000,008 | 3,953,270 | Oct 03, 2017, 06:08 PM |
| MARCUS JOEL S | Director | Jan 26, 2017 | Option Exercise | $2.60 | 95,000 | 247,450 | 116,671 | Jan 30, 2017, 06:13 PM |
| Vanover Kimberly E. | SVP, Clinical Development | Jan 05, 2017 | Sale | $16.59 | 800 | 13,272 | 10,128 | Jan 09, 2017, 05:34 PM |
| Mates Sharon | Chairman, President & CEO | Jan 05, 2017 | Sale | $16.55 | 4,081 | 67,541 | 1,088,707 | Jan 09, 2017, 05:31 PM |
| Hineline Lawrence J. | VP of Finance CFO | Jan 05, 2017 | Sale | $16.58 | 1,918 | 31,800 | 63,389 | Jan 09, 2017, 05:29 PM |
| Halstead Michael | SVP and General Counsel | Jan 05, 2017 | Sale | $16.55 | 1,601 | 26,497 | 21,506 | Jan 09, 2017, 05:27 PM |
| Vanover Kimberly E. | SVP, Clinical Development | Dec 15, 2016 | Option Exercise | $1.46 | 18,750 | 27,425 | 12,500 | Dec 19, 2016, 05:50 PM |
| Vanover Kimberly E. | SVP, Clinical Development | Dec 15, 2016 | Sale | $15.23 | 9,375 | 142,773 | 9,375 | Dec 19, 2016, 05:50 PM |
| ALAFI MOSHE | 10% Owner | Dec 07, 2016 | Buy | $16.14 | 20,826 | 336,038 | 3,695,205 | Dec 07, 2016, 04:35 PM |
| ALAFI MOSHE | 10% Owner | Dec 06, 2016 | Buy | $16.33 | 44,174 | 721,445 | 3,674,379 | Dec 07, 2016, 04:35 PM |
| Alafi Christopher D | Director | Dec 07, 2016 | Buy | $16.14 | 20,826 | 336,038 | 3,695,205 | Dec 07, 2016, 04:32 PM |
| Alafi Christopher D | Director | Dec 06, 2016 | Buy | $16.33 | 44,174 | 721,445 | 3,674,379 | Dec 07, 2016, 04:32 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Dec 07, 2016 | Buy | $16.14 | 20,826 | 336,038 | 3,695,205 | Dec 07, 2016, 04:21 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Dec 06, 2016 | Buy | $16.33 | 44,174 | 721,445 | 3,674,379 | Dec 07, 2016, 04:21 PM |
| ALAFI MOSHE | 10% Owner | Nov 14, 2016 | Buy | $14.50 | 34,000 | 492,969 | 3,630,205 | Nov 17, 2016, 04:35 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Nov 14, 2016 | Buy | $14.50 | 34,000 | 492,969 | 3,630,205 | Nov 17, 2016, 04:34 PM |
| Alafi Christopher D | Director | Nov 14, 2016 | Buy | $14.50 | 34,000 | 492,969 | 3,630,205 | Nov 17, 2016, 04:32 PM |
| RIGGS RORY B | Director | Feb 05, 2014 | Buy | $17.50 | 14,285 | 249,988 | 26,091 | Apr 20, 2016, 04:30 PM |
| RIGGS RORY B | Director | Feb 05, 2014 | Buy | $17.50 | 14,286 | 250,005 | 226,670 | Apr 20, 2016, 04:30 PM |
| Alafi Christopher D | Director | Feb 29, 2016 | Buy | $29.70 | 100,000 | 2,970,300 | 728,828 | Feb 29, 2016, 05:32 PM |
| LERNER RICHARD A | Director | Feb 18, 2016 | Option Exercise | $1.36 | 10,000 | 13,600 | 47,500 | Feb 19, 2016, 04:25 PM |
| VAN NOSTRAND ROBERT L | Director | Dec 31, 2015 | Option Exercise | $53.79 | 69 | 3,712 | 1,365 | Jan 05, 2016, 07:09 PM |
| RIGGS RORY B | Director | Dec 31, 2015 | Option Exercise | $53.79 | 197 | 10,597 | 15,679 | Jan 05, 2016, 05:13 PM |
| MARCUS JOEL S | Director | Dec 31, 2015 | Option Exercise | $53.79 | 199 | 10,704 | 18,921 | Jan 05, 2016, 05:11 PM |
| Alafi Christopher D | Director | Dec 31, 2015 | Option Exercise | $53.79 | 195 | 10,489 | 628,828 | Jan 05, 2016, 05:00 PM |
| LERNER RICHARD A | Director | Dec 31, 2015 | Option Exercise | $53.79 | 188 | 10,113 | 3,266 | Jan 05, 2016, 04:59 PM |
| Mates Sharon | Chairman, President & CEO | Dec 11, 2015 | Option Exercise | $1.12 | 68,750 | 77,125 | 1,137,685 | Dec 15, 2015, 08:27 PM |
| Mates Sharon | Chairman, President & CEO | Dec 11, 2015 | Sale | $53.87 | 51,500 | 2,774,441 | 1,107,639 | Dec 15, 2015, 08:27 PM |
| Hineline Lawrence J. | VP of Finance CFO | Dec 15, 2015 | Option Exercise | $1.45 | 35,000 | 50,750 | 74,700 | Dec 15, 2015, 08:25 PM |
| Hineline Lawrence J. | VP of Finance CFO | Dec 14, 2015 | Option Exercise | $0.60 | 7,500 | 4,500 | 72,200 | Dec 15, 2015, 08:25 PM |
| Hineline Lawrence J. | VP of Finance CFO | Nov 24, 2015 | Option Exercise | $0.60 | 5,000 | 3,000 | 64,700 | Dec 15, 2015, 08:25 PM |
| Hineline Lawrence J. | VP of Finance CFO | Dec 15, 2015 | Sale | $51.97 | 22,500 | 1,169,226 | 63,464 | Dec 15, 2015, 08:25 PM |
| Hineline Lawrence J. | VP of Finance CFO | Dec 14, 2015 | Sale | $50.94 | 22,500 | 1,146,140 | 62,307 | Dec 15, 2015, 08:25 PM |
| MARCUS JOEL S | Director | Dec 08, 2015 | Sale | $54.80 | 22,700 | 1,243,960 | 1,191,156 | Dec 08, 2015, 05:30 PM |
| MARCUS JOEL S | Director | Dec 07, 2015 | Sale | $53.17 | 40,000 | 2,126,628 | 1,238,781 | Dec 08, 2015, 05:30 PM |
| MARCUS JOEL S | Director | Dec 04, 2015 | Sale | $55.96 | 30,000 | 1,678,800 | 1,253,856 | Dec 08, 2015, 05:30 PM |
| Hineline Lawrence J. | VP of Finance CFO | Nov 24, 2015 | Sale | $55.00 | 5,000 | 275,000 | 59,700 | Nov 27, 2015, 08:29 AM |
| Fienberg Allen A. | VP of Business Development | Sep 09, 2015 | Option Exercise | $1.36 | 12,500 | 17,000 | 295,000 | Sep 11, 2015, 04:53 PM |
| Fienberg Allen A. | VP of Business Development | Aug 19, 2015 | Sale | $30.30 | 10,000 | 303,000 | 198,023 | Sep 11, 2015, 04:53 PM |
| Fienberg Allen A. | VP of Business Development | Aug 21, 2015 | Sale | $30.30 | 200 | 6,060 | 197,823 | Sep 11, 2015, 04:53 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Jun 08, 2015 | Sale | $26.84 | 25,000 | 671,000 | 126,500 | Jun 09, 2015, 05:04 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | May 19, 2015 | Option Exercise | $1.23 | 47,500 | 58,250 | 151,500 | May 20, 2015, 05:19 PM |
| Fienberg Allen A. | VP of Business Development | Mar 31, 2015 | Option Exercise | $0.60 | 12,500 | 7,500 | 282,500 | Apr 02, 2015, 04:59 PM |
| MARCUS JOEL S | Director | Mar 31, 2015 | Option Exercise | $1.23 | 15,000 | 18,400 | 18,118 | Apr 02, 2015, 04:58 PM |
| Alafi Christopher D | Director | Mar 11, 2015 | Buy | $24.00 | 625,000 | 15,000,000 | 627,604 | Mar 12, 2015, 06:24 PM |
| Fienberg Allen A. | VP of Business Development | Jan 14, 2015 | Sale | $19.00 | 5,000 | 95,000 | 270,000 | Jan 16, 2015, 04:31 PM |
| Hineline Lawrence J. | VP of Finance CFO | Dec 09, 2014 | Sale | $16.52 | 11,535 | 190,558 | 64,700 | Dec 10, 2014, 05:11 PM |
| Hineline Lawrence J. | VP of Finance CFO | Dec 08, 2014 | Sale | $16.91 | 10,965 | 185,418 | 76,235 | Dec 10, 2014, 05:11 PM |
| Hineline Lawrence J. | VP of Finance CFO | Dec 02, 2014 | Option Exercise | $0.50 | 37,200 | 18,600 | 87,200 | Dec 03, 2014, 05:43 PM |
| Alafi Christopher D | Director | Dec 01, 2014 | Buy | $14.75 | 1,422 | 20,975 | 3,596,205 | Dec 03, 2014, 05:42 PM |
| ALAFI MOSHE | 10% Owner | Dec 01, 2014 | Buy | $14.75 | 1,422 | 20,975 | 3,596,205 | Dec 03, 2014, 05:40 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Dec 01, 2014 | Buy | $14.75 | 1,422 | 20,975 | 3,596,205 | Dec 03, 2014, 05:39 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Nov 28, 2014 | Buy | $14.75 | 35,000 | 516,250 | 3,594,783 | Nov 28, 2014, 04:42 PM |
| ALAFI MOSHE | 10% Owner | Nov 28, 2014 | Buy | $14.75 | 35,000 | 516,250 | 3,594,783 | Nov 28, 2014, 04:38 PM |
| Alafi Christopher D | Director | Nov 28, 2014 | Buy | $14.75 | 35,000 | 516,250 | 3,594,783 | Nov 28, 2014, 04:36 PM |
| Mates Sharon | Chairman, President & CEO | Nov 25, 2014 | Option Exercise | $0.50 | 50,000 | 25,000 | 1,103,935 | Nov 28, 2014, 04:31 PM |
| Mates Sharon | Chairman, President & CEO | Nov 28, 2014 | Sale | $14.75 | 35,000 | 516,250 | 1,068,935 | Nov 28, 2014, 04:31 PM |
| Alafi Christopher D | Director | Nov 19, 2014 | Buy | $14.25 | 1,034 | 14,735 | 3,559,783 | Nov 21, 2014, 06:04 PM |
| ALAFI MOSHE | 10% Owner | Nov 19, 2014 | Buy | $14.25 | 1,034 | 14,735 | 3,559,783 | Nov 21, 2014, 06:00 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Nov 19, 2014 | Buy | $14.25 | 1,034 | 14,735 | 3,559,783 | Nov 21, 2014, 05:58 PM |
| Alafi Christopher D | Director | Nov 14, 2014 | Buy | $15.07 | 133 | 2,004 | 3,555,218 | Nov 18, 2014, 05:46 PM |
| Alafi Christopher D | Director | Nov 18, 2014 | Buy | $14.23 | 3,531 | 50,246 | 3,558,749 | Nov 18, 2014, 05:46 PM |
| ALAFI MOSHE | 10% Owner | Nov 18, 2014 | Buy | $14.23 | 3,531 | 50,246 | 3,558,749 | Nov 18, 2014, 05:45 PM |
| ALAFI MOSHE | 10% Owner | Nov 14, 2014 | Buy | $15.07 | 133 | 2,004 | 3,555,218 | Nov 18, 2014, 05:45 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Nov 18, 2014 | Buy | $14.23 | 3,531 | 50,246 | 3,558,749 | Nov 18, 2014, 05:43 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Nov 14, 2014 | Buy | $15.07 | 133 | 2,004 | 3,555,218 | Nov 18, 2014, 05:43 PM |
| Alafi Christopher D | Director | Nov 13, 2014 | Buy | $15.12 | 2,200 | 33,264 | 3,555,085 | Nov 13, 2014, 05:04 PM |
| Alafi Christopher D | Director | Nov 12, 2014 | Buy | $15.23 | 5,000 | 76,150 | 3,552,885 | Nov 13, 2014, 05:04 PM |
| Alafi Christopher D | Director | Nov 11, 2014 | Buy | $15.55 | 5,000 | 77,750 | 3,547,885 | Nov 13, 2014, 05:04 PM |
| ALAFI MOSHE | 10% Owner | Nov 12, 2014 | Buy | $15.23 | 5,000 | 76,150 | 3,552,885 | Nov 13, 2014, 05:01 PM |
| ALAFI MOSHE | 10% Owner | Nov 11, 2014 | Buy | $15.55 | 5,000 | 77,750 | 3,547,885 | Nov 13, 2014, 05:01 PM |
| ALAFI MOSHE | 10% Owner | Nov 13, 2014 | Buy | $15.12 | 2,200 | 33,264 | 3,555,085 | Nov 13, 2014, 05:01 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Nov 13, 2014 | Buy | $15.12 | 2,200 | 33,264 | 3,555,085 | Nov 13, 2014, 04:59 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Nov 12, 2014 | Buy | $15.23 | 5,000 | 76,150 | 3,552,885 | Nov 13, 2014, 04:59 PM |
| ALAFI CAPITAL CO LLC | 10% Owner | Nov 11, 2014 | Buy | $15.55 | 5,000 | 77,750 | 3,547,885 | Nov 13, 2014, 04:59 PM |
| Halstead Michael | SVP and General Counsel | Nov 06, 2014 | Buy | $15.47 | 13,000 | 201,110 | 20,000 | Nov 06, 2014, 04:53 PM |
| Halstead Michael | SVP and General Counsel | Nov 05, 2014 | Buy | $15.21 | 7,000 | 106,470 | 7,000 | Nov 06, 2014, 04:53 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 16, 2014 | Sale | $15.00 | 5,152 | 77,280 | 104,000 | Oct 17, 2014, 05:00 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 15, 2014 | Sale | $15.00 | 2,004 | 30,060 | 109,152 | Oct 15, 2014, 04:52 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 13, 2014 | Sale | $15.00 | 1,600 | 24,000 | 111,156 | Oct 15, 2014, 04:52 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 08, 2014 | Sale | $15.00 | 4,745 | 71,175 | 112,756 | Oct 10, 2014, 05:05 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 06, 2014 | Sale | $15.00 | 636 | 9,540 | 117,501 | Oct 07, 2014, 04:30 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 03, 2014 | Sale | $15.00 | 15,863 | 237,945 | 118,137 | Oct 07, 2014, 04:30 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Sep 15, 2014 | Sale | $15.00 | 5,000 | 75,000 | 134,000 | Sep 17, 2014, 05:12 PM |
| Hineline Lawrence J. | VP of Finance CFO | Sep 08, 2014 | Option Exercise | $0.50 | 300 | 150 | 50,300 | Sep 10, 2014, 05:33 PM |
| Hineline Lawrence J. | VP of Finance CFO | Sep 08, 2014 | Sale | $15.00 | 300 | 4,500 | 50,000 | Sep 10, 2014, 05:33 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | Jul 21, 2014 | Option Exercise | $0.50 | 37,500 | 18,750 | 139,000 | Jul 22, 2014, 05:31 PM |
| ALAFI MOSHE | 10% Owner | Jun 19, 2014 | Sale | $6.35 | 15,742 | 100,006 | 0 | Jul 10, 2014, 04:56 PM |
| Fienberg Allen A. | VP of Business Development | May 28, 2014 | Option Exercise | $0.50 | 37,500 | 18,750 | 275,000 | Jun 06, 2014, 05:23 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | May 27, 2014 | Sale | $15.00 | 5,000 | 75,000 | 101,500 | May 29, 2014, 06:30 PM |
| Wennogle Lawrence P. | Vice President, Drug Discovery | May 22, 2014 | Sale | $15.00 | 6,000 | 89,983 | 110,806 | May 23, 2014, 07:46 PM |
| RIGGS RORY B | Director | Feb 05, 2014 | Buy | $17.50 | 28,571 | 499,993 | 240,955 | Feb 05, 2014, 04:56 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Mates Sharon | Chairman and CEO | 08/30/2024 | 437,861 |
| Mates Sharon | Chairman and CEO | 08/29/2024 | 453,239 |
| Mates Sharon | Chairman and CEO | 08/30/2024 | 2,505,351 |
| Mates Sharon | Chairman and CEO | 08/29/2024 | 2,583,884 |
| Mates Sharon | Chairman and CEO | 08/28/2024 | 574,521 |
| Mates Sharon | Chairman and CEO | 08/27/2024 | 711,813 |
| Mates Sharon | Chairman and CEO | 08/26/2024 | 399,067 |
| Mates Sharon | Chairman and CEO | 08/27/2024 | 2,981,056 |
| Mates Sharon | Chairman and CEO | 08/26/2024 | 1,694,229 |
| Mates Sharon | Chairman and CEO | 08/28/2024 | 2,378,801 |
| Mates Sharon | Chairman and CEO | 08/22/2024 | 691,907 |
| Mates Sharon | Chairman and CEO | 08/21/2024 | 931,438 |
| Mates Sharon | Chairman and CEO | 08/23/2024 | 503,908 |
| Mates Sharon | Chairman and CEO | 08/22/2024 | 2,940,802 |
| Mates Sharon | Chairman and CEO | 08/21/2024 | 4,010,501 |
| Mates Sharon | Chairman and CEO | 08/23/2024 | 2,135,435 |
| Neumann Mark | EVP, Chief Commercial Officer | 08/16/2024 | 690,359 |
| Neumann Mark | EVP, Chief Commercial Officer | 08/16/2024 | 1,405,047 |
| VAN NOSTRAND ROBERT L | Director | 06/28/2024 | 5,685 |
| RIGGS RORY B | Director | 06/28/2024 | 17,944 |
| RIGGS RORY B | Director | 06/24/2024 | 337,200 |
| RIGGS RORY B | Director | 06/24/2024 | 337,193 |
| VAN NOSTRAND ROBERT L | Director | 06/18/2024 | 337,200 |
| VAN NOSTRAND ROBERT L | Director | 06/18/2024 | 1,518,199 |
| Mates Sharon | Chairman and CEO | 04/24/2024 | 345,618 |
| VAN NOSTRAND ROBERT L | Director | 03/31/2024 | 5,467 |
| RIGGS RORY B | Director | 03/31/2024 | 17,992 |
| RIGGS RORY B | Director | 03/20/2024 | 371,200 |
| Mates Sharon | Chairman, President & CEO | 03/11/2024 | 1,341,123 |
| Mates Sharon | Chairman, President & CEO | 03/07/2024 | 2,707,277 |
| Hineline Lawrence J. | SVP of Finance, CFO | 03/10/2024 | 257,497 |
| Hineline Lawrence J. | SVP of Finance, CFO | 03/11/2024 | 667,587 |
| Hineline Lawrence J. | SVP of Finance, CFO | 03/07/2024 | 874,560 |
| Halstead Michael | EVP and General Counsel | 03/11/2024 | 484,537 |
| Halstead Michael | EVP and General Counsel | 03/07/2024 | 868,698 |
| Neumann Mark | EVP, Chief Commercial Officer | 03/07/2024 | 874,179 |
| Neumann Mark | EVP, Chief Commercial Officer | 03/11/2024 | 481,931 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 03/11/2024 | 243,482 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 03/07/2024 | 429,308 |
| VAN NOSTRAND ROBERT L | Director | 02/27/2024 | 371,200 |
| VAN NOSTRAND ROBERT L | Director | 02/27/2024 | 1,458,650 |
| Halstead Michael | EVP and General Counsel | 02/26/2024 | 549,784 |
| Hineline Lawrence J. | SVP of Finance, CFO | 02/26/2024 | 216,987 |
| Hineline Lawrence J. | SVP of Finance, CFO | 02/26/2024 | 925,961 |
| Mates Sharon | Chairman, President & CEO | 02/26/2024 | 1,576,464 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 02/26/2024 | 288,534 |
| Neumann Mark | EVP, Chief Commercial Officer | 02/26/2024 | 554,491 |
| MARCUS JOEL S | Director | 02/26/2024 | 1,798,678 |
| MARCUS JOEL S | Director | 02/26/2024 | 1,808,253 |
| Halstead Michael | EVP and General Counsel | 02/02/2024 | 787,719 |
| Mates Sharon | Chairman, President & CEO | 02/02/2024 | 2,272,693 |
| Neumann Mark | EVP, Chief Commercial Officer | 02/02/2024 | 796,367 |
| Hineline Lawrence J. | SVP of Finance, CFO | 02/02/2024 | 745,037 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 02/02/2024 | 414,355 |
| Mates Sharon | Chairman, President & CEO | 01/17/2024 | 810,696 |
| Mates Sharon | Chairman, President & CEO | 01/16/2024 | 1,270,587 |
| Mates Sharon | Chairman, President & CEO | 01/18/2024 | 1,145,081 |
| Mates Sharon | Chairman, President & CEO | 01/16/2024 | 5,067,982 |
| Mates Sharon | Chairman, President & CEO | 01/18/2024 | 4,427,849 |
| Mates Sharon | Chairman, President & CEO | 01/17/2024 | 3,185,062 |
| Halstead Michael | EVP and General Counsel | 01/11/2024 | 680,051 |
| Halstead Michael | EVP and General Counsel | 01/11/2024 | 3,341,698 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 01/02/2024 | 1,237,543 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 01/02/2024 | 4,397,113 |
| RIGGS RORY B | Director | 12/31/2023 | 17,977 |
| VAN NOSTRAND ROBERT L | Director | 12/31/2023 | 5,443 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 12/13/2023 | 1,382,030 |
| Halstead Michael | EVP and General Counsel | 11/13/2023 | 678,049 |
| Halstead Michael | EVP and General Counsel | 11/13/2023 | 2,694,783 |
| Neumann Mark | EVP, Chief Commercial Officer | 11/06/2023 | 640,491 |
| Neumann Mark | EVP, Chief Commercial Officer | 11/06/2023 | 2,358,152 |
| VAN NOSTRAND ROBERT L | Director | 09/30/2023 | 5,469 |
| RIGGS RORY B | Director | 09/30/2023 | 17,971 |
| Mates Sharon | Chairman, President & CEO | 09/19/2023 | 2,405,852 |
| Mates Sharon | Chairman, President & CEO | 09/18/2023 | 2,988,213 |
| Neumann Mark | EVP, Chief Commercial Officer | 08/07/2023 | 1,028,027 |
| Neumann Mark | EVP, Chief Commercial Officer | 08/07/2023 | 3,251,087 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 07/17/2023 | 119,730 |
| VAN NOSTRAND ROBERT L | Director | 06/30/2023 | 5,382 |
| Hineline Lawrence J. | SVP of Finance CFO | 06/14/2023 | 3,462,317 |
| Hineline Lawrence J. | SVP of Finance CFO | 06/14/2023 | 5,236,329 |
| VAN NOSTRAND ROBERT L | Director | 04/17/2023 | 130,500 |
| VAN NOSTRAND ROBERT L | Director | 04/17/2023 | 630,000 |
| RIGGS RORY B | Director | 03/31/2023 | 16,949 |
| Neumann Mark | EVP, Chief Commercial Officer | 03/28/2023 | 847,380 |
| Durgam Suresh K. | EVP, Chief Medical Officer | 03/13/2023 | 330,794 |
| Neumann Mark | EVP, Chief Commercial Officer | 03/13/2023 | 169,042 |
| Neumann Mark | EVP, Chief Commercial Officer | 03/10/2023 | 370,557 |
| Halstead Michael | EVP and General Counsel | 03/10/2023 | 720,086 |
| Halstead Michael | EVP and General Counsel | 03/13/2023 | 330,007 |
| Hineline Lawrence J. | SVP of Finance CFO | 03/13/2023 | 250,808 |
| Hineline Lawrence J. | SVP of Finance CFO | 03/10/2023 | 674,417 |
| Mates Sharon | Chairman, President & CEO | 03/13/2023 | 65,200 |
| Mates Sharon | Chairman, President & CEO | 03/13/2023 | 925,275 |
| Mates Sharon | Chairman, President & CEO | 03/10/2023 | 1,802,566 |
| Neumann Mark | EVP, Chief Commercial Officer | 03/01/2023 | 362,122 |
| Neumann Mark | EVP, Chief Commercial Officer | 02/24/2023 | 190,648 |
| Durgam Suresh K. | SVP, Chief Medical Officer | 02/24/2023 | 372,689 |
| Halstead Michael | EVP and General Counsel | 02/24/2023 | 371,819 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/24/2023 | 350,609 |
| Mates Sharon | Chairman, President & CEO | 02/24/2023 | 97,800 |
| Mates Sharon | Chairman, President & CEO | 02/24/2023 | 1,062,408 |
| Neumann Mark | EVP, Chief Commercial Officer | 02/21/2023 | 183,246 |
| Durgam Suresh K. | SVP, Chief Medical Officer | 02/21/2023 | 391,304 |
| Halstead Michael | EVP and General Counsel | 02/21/2023 | 521,699 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/17/2023 | 687,013 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/21/2023 | 488,891 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/17/2023 | 2,689,464 |
| Mates Sharon | Chairman, President & CEO | 02/21/2023 | 1,304,000 |
| VAN NOSTRAND ROBERT L | Director | 12/30/2022 | 5,133 |
| RIGGS RORY B | Director | 12/30/2022 | 16,987 |
| MARCUS JOEL S | Director | 12/19/2022 | 254,100 |
| Mates Sharon | Chairman, President & CEO | 12/13/2022 | 1,819,565 |
| Halstead Michael | EVP and General Counsel | 12/01/2022 | 773,500 |
| Halstead Michael | EVP and General Counsel | 12/01/2022 | 2,686,514 |
| MARCUS JOEL S | Director | 11/07/2022 | 523,023 |
| VAN NOSTRAND ROBERT L | Director | 09/30/2022 | 5,118 |
| RIGGS RORY B | Director | 09/30/2022 | 16,983 |
| Hineline Lawrence J. | SVP of Finance CFO | 09/21/2022 | 1,008,087 |
| Hineline Lawrence J. | SVP of Finance CFO | 09/21/2022 | 2,973,406 |
| VAN NOSTRAND ROBERT L | Director | 08/11/2022 | 379,500 |
| VAN NOSTRAND ROBERT L | Director | 08/11/2022 | 1,713,975 |
| MARCUS JOEL S | Director | 08/11/2022 | 592,200 |
| RIGGS RORY B | Director | 06/30/2022 | 16,496 |
| MARCUS JOEL S | Director | 05/12/2022 | 550,000 |
| Neumann Mark | EVP, Chief Commercial Officer | 04/08/2022 | 1,099,210 |
| Neumann Mark | EVP, Chief Commercial Officer | 04/08/2022 | 5,558,051 |
| VAN NOSTRAND ROBERT L | Director | 03/31/2022 | 7,710 |
| RIGGS RORY B | Director | 03/31/2022 | 15,726 |
| RIGGS RORY B | Director | 03/18/2022 | 1,262,505 |
| RIGGS RORY B | Director | 03/17/2022 | 8,536,646 |
| RIGGS RORY B | Director | 03/16/2022 | 3,824,827 |
| Mates Sharon | Chairman, President & CEO | 03/09/2022 | 110,547 |
| MARCUS JOEL S | Director | 03/08/2022 | 790,150 |
| MARCUS JOEL S | Director | 03/07/2022 | 272,600 |
| Durgam Suresh K. | Chief Medical Officer | 03/04/2022 | 214,307 |
| Durgam Suresh K. | Chief Medical Officer | 03/02/2022 | 238,005 |
| Durgam Suresh K. | Chief Medical Officer | 02/24/2022 | 211,468 |
| Neumann Mark | EVP, Chief Commercial Officer | 02/24/2022 | 412,810 |
| Halstead Michael | EVP and General Counsel | 02/24/2022 | 410,933 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/24/2022 | 387,349 |
| Mates Sharon | Chairman, President & CEO | 02/24/2022 | 1,174,074 |
| Durgam Suresh K. | Chief Medical Officer | 02/22/2022 | 230,958 |
| Neumann Mark | EVP, Chief Commercial Officer | 02/22/2022 | 615,827 |
| Halstead Michael | EVP and General Counsel | 02/22/2022 | 617,100 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/22/2022 | 578,506 |
| Mates Sharon | Chairman, President & CEO | 02/22/2022 | 1,542,413 |
| Durgam Suresh K. | Chief Medical Officer | 01/18/2022 | 261,553 |
| Durgam Suresh K. | Chief Medical Officer | 01/10/2022 | 280,020 |
| Neumann Mark | EVP, Chief Commercial Officer | 01/10/2022 | 854,255 |
| Halstead Michael | EVP and General Counsel | 01/10/2022 | 800,774 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/10/2022 | 800,420 |
| Mates Sharon | Chairman, President & CEO | 01/10/2022 | 1,708,429 |
| VAN NOSTRAND ROBERT L | Director | 12/31/2021 | 7,746 |
| RIGGS RORY B | Director | 12/31/2021 | 15,702 |
| Halstead Michael | EVP and General Counsel | 12/21/2021 | 2,897,494 |
| Halstead Michael | EVP and General Counsel | 12/21/2021 | 8,412,278 |
| Hineline Lawrence J. | SVP of Finance CFO | 12/21/2021 | 2,941,951 |
| Hineline Lawrence J. | SVP of Finance CFO | 12/21/2021 | 8,328,664 |
| Neumann Mark | EVP, Chief Commercial Officer | 10/18/2021 | 549,551 |
| Mates Sharon | Chairman, President & CEO | 10/15/2021 | 3,053 |
| Mates Sharon | Chairman, President & CEO | 10/18/2021 | 327,680 |
| Mates Sharon | Chairman, President & CEO | 10/15/2021 | 1,615,680 |
| Mates Sharon | Chairman, President & CEO | 10/14/2021 | 56,640 |
| LERNER RICHARD A | Director | 09/30/2021 | 14,987 |
| RIGGS RORY B | Director | 09/30/2021 | 15,732 |
| VAN NOSTRAND ROBERT L | Director | 09/30/2021 | 8,015 |
| Mates Sharon | Chairman, President & CEO | 08/23/2021 | 28,400 |
| VAN NOSTRAND ROBERT L | Director | 06/30/2021 | 7,062 |
| RIGGS RORY B | Director | 06/30/2021 | 15,716 |
| LERNER RICHARD A | Director | 06/30/2021 | 14,981 |
| Alafi Christopher D | Director | 05/24/2021 | 1,075,490 |
| Alafi Christopher D | Director | 05/21/2021 | 44,000 |
| LERNER RICHARD A | Director | 03/31/2021 | 14,997 |
| MARCUS JOEL S | Director | 03/02/2021 | 531,600 |
| MARCUS JOEL S | Director | 03/02/2021 | 532,683 |
| Durgam Suresh K. | Chief Medical Officer | 02/19/2021 | 107,310 |
| Neumann Mark | EVP, Chief Commercial Officer | 02/19/2021 | 203,308 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/19/2021 | 409,625 |
| Halstead Michael | EVP and General Counsel | 02/19/2021 | 437,133 |
| Mates Sharon | Chairman, President & CEO | 02/19/2021 | 1,092,436 |
| Durgam Suresh K. | Chief Medical Officer | 01/11/2021 | 140,259 |
| Neumann Mark | EVP, Chief Commercial Officer | 01/11/2021 | 310,082 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/11/2021 | 628,769 |
| Halstead Michael | EVP and General Counsel | 01/11/2021 | 628,978 |
| Mates Sharon | Chairman, President & CEO | 01/11/2021 | 1,341,260 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/04/2021 | 495,008 |
| Halstead Michael | EVP and General Counsel | 01/04/2021 | 505,834 |
| Mates Sharon | Chairman, President & CEO | 01/04/2021 | 1,513,271 |
| LERNER RICHARD A | Director | 12/31/2020 | 14,978 |
| VAN NOSTRAND ROBERT L | Director | 12/31/2020 | 7,060 |
| RIGGS RORY B | Director | 12/31/2020 | 15,741 |
| Alafi Christopher D | Director | 12/31/2020 | 15,741 |
| Mates Sharon | Chairman, President & CEO | 12/18/2020 | 93,160 |
| Halstead Michael | EVP and General Counsel | 11/17/2020 | 1,039,500 |
| Halstead Michael | EVP and General Counsel | 11/17/2020 | 2,193,446 |
| Hineline Lawrence J. | SVP of Finance CFO | 11/11/2020 | 61,000 |
| Hineline Lawrence J. | SVP of Finance CFO | 11/11/2020 | 712,344 |
| Mates Sharon | Chairman, President & CEO | 11/10/2020 | 1,317,101 |
| Mates Sharon | Chairman, President & CEO | 11/04/2020 | 1,250,000 |
| Neumann Mark | EVP, Chief Commercial Officer | 10/16/2020 | 182,026 |
| VAN NOSTRAND ROBERT L | Director | 09/30/2020 | 7,082 |
| RIGGS RORY B | Director | 09/30/2020 | 15,730 |
| LERNER RICHARD A | Director | 09/30/2020 | 14,985 |
| Alafi Christopher D | Director | 09/30/2020 | 15,730 |
| Alafi Christopher D | Director | 09/14/2020 | 1,465,200 |
| Hineline Lawrence J. | SVP of Finance CFO | 09/09/2020 | 343,494 |
| Hineline Lawrence J. | SVP of Finance CFO | 09/09/2020 | 1,307,351 |
| Alafi Christopher D | Director | 09/11/2020 | 589,680 |
| VAN NOSTRAND ROBERT L | Director | 06/30/2020 | 7,059 |
| LERNER RICHARD A | Director | 06/30/2020 | 14,991 |
| RIGGS RORY B | Director | 06/30/2020 | 15,736 |
| Alafi Christopher D | Director | 06/30/2020 | 15,736 |
| MARCUS JOEL S | Director | 05/14/2020 | 192,424 |
| MARCUS JOEL S | Director | 05/11/2020 | 997,500 |
| MARCUS JOEL S | Director | 05/13/2020 | 150,537 |
| LERNER RICHARD A | Director | 05/11/2020 | 68,500 |
| LERNER RICHARD A | Director | 05/11/2020 | 71,750 |
| Alafi Christopher D | Director | 03/31/2020 | 15,739 |
| LERNER RICHARD A | Director | 03/31/2020 | 14,986 |
| VAN NOSTRAND ROBERT L | Director | 03/31/2020 | 7,070 |
| RIGGS RORY B | Director | 03/31/2020 | 15,739 |
| Halstead Michael | EVP and General Counsel | 01/24/2020 | 89,930 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/24/2020 | 89,930 |
| Mates Sharon | Chairman, President & CEO | 01/24/2020 | 220,116 |
| LERNER RICHARD A | Director | 12/31/2019 | 13,724 |
| Satlin Andrew | EVP and Chief Medical Officer | 01/09/2020 | 302,750 |
| Neumann Mark | EVP, Chief Commercial Officer | 01/08/2020 | 162,175 |
| Mates Sharon | Chairman, President & CEO | 01/09/2020 | 1,095,973 |
| Halstead Michael | EVP and General Counsel | 01/09/2020 | 513,730 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/09/2020 | 513,730 |
| Mates Sharon | Chairman, President & CEO | 01/08/2020 | 164,400 |
| Mates Sharon | Chairman, President & CEO | 01/06/2020 | 1,380,880 |
| Halstead Michael | EVP and General Counsel | 01/06/2020 | 651,007 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/06/2020 | 650,003 |
| Halstead Michael | EVP and General Counsel | 01/02/2020 | 253,214 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/02/2020 | 253,165 |
| Mates Sharon | Chairman, President & CEO | 12/31/2019 | 16,440 |
| Mates Sharon | Chairman, President & CEO | 01/02/2020 | 567,230 |
| VAN NOSTRAND ROBERT L | Director | 12/31/2019 | 5,833 |
| RIGGS RORY B | Director | 12/31/2019 | 14,479 |
| Alafi Christopher D | Director | 12/31/2019 | 14,479 |
| Hineline Lawrence J. | SVP of Finance CFO | 12/23/2019 | 26,304 |
| Hineline Lawrence J. | SVP of Finance CFO | 12/23/2019 | 383,316 |
| Neumann Mark | EVP, Chief Commercial Officer | 10/16/2019 | 55,886 |
| RIGGS RORY B | Director | 09/30/2019 | 14,499 |
| LERNER RICHARD A | Director | 09/30/2019 | 13,745 |
| VAN NOSTRAND ROBERT L | Director | 09/30/2019 | 5,827 |
| Alafi Christopher D | Director | 09/30/2019 | 14,499 |
| Alafi Christopher D | Director | 09/10/2019 | 4,974,678 |
| Alafi Christopher D | Director | 08/30/2019 | 1,065,212 |
| VAN NOSTRAND ROBERT L | Director | 06/28/2019 | 5,828 |
| LERNER RICHARD A | Director | 06/28/2019 | 13,746 |
| RIGGS RORY B | Director | 06/28/2019 | 14,499 |
| Alafi Christopher D | Director | 06/28/2019 | 14,499 |
| Alafi Christopher D | Director | 11/22/2017 | 155,500 |
| Alafi Christopher D | Director | 06/12/2019 | 1,993,793 |
| MARCUS JOEL S | Director | 05/29/2019 | 249,000 |
| Alafi Christopher D | Director | 05/14/2019 | 1,256,350 |
| Alafi Christopher D | Director | 03/31/2019 | 14,494 |
| VAN NOSTRAND ROBERT L | Director | 03/31/2019 | 5,822 |
| RIGGS RORY B | Director | 03/31/2019 | 14,494 |
| LERNER RICHARD A | Director | 03/31/2019 | 13,739 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/27/2019 | 28,496 |
| Hineline Lawrence J. | SVP of Finance CFO | 02/27/2019 | 15,000 |
| Mates Sharon | Chairman, President & CEO | 01/07/2019 | 82,088 |
| Mates Sharon | Chairman, President & CEO | 01/04/2019 | 522,222 |
| Halstead Michael | EVP and General Counsel | 01/07/2019 | 38,601 |
| Halstead Michael | EVP and General Counsel | 01/04/2019 | 245,817 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/07/2019 | 38,601 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/04/2019 | 245,782 |
| Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | 01/07/2019 | 7,276 |
| Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | 01/04/2019 | 109,704 |
| Davis Robert E | SVP, Chief Scientific Officer | 01/04/2019 | 109,630 |
| Mates Sharon | Chairman, President & CEO | 01/02/2019 | 193,831 |
| Halstead Michael | EVP and General Counsel | 01/02/2019 | 86,580 |
| Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | 01/02/2019 | 53,657 |
| Davis Robert E | SVP, Chief Scientific Officer | 01/02/2019 | 53,706 |
| Hineline Lawrence J. | SVP of Finance CFO | 01/02/2019 | 86,580 |
| VAN NOSTRAND ROBERT L | Director | 12/31/2018 | 5,832 |
| RIGGS RORY B | Director | 12/31/2018 | 14,499 |
| LERNER RICHARD A | Director | 12/31/2018 | 13,748 |
| Alafi Christopher D | Director | 12/31/2018 | 14,499 |
| Mates Sharon | Chairman, President & CEO | 12/10/2018 | 75,000 |
| Davis Robert E | SVP, Chief Scientific Officer | 12/06/2018 | 12,163 |
| MARCUS JOEL S | Director | 11/12/2018 | 125,580 |
| MARCUS JOEL S | Director | 11/09/2018 | 456,000 |
| LERNER RICHARD A | Director | 10/22/2018 | 18,750 |
| LERNER RICHARD A | Director | 09/30/2018 | 13,736 |
| RIGGS RORY B | Director | 09/30/2018 | 14,496 |
| VAN NOSTRAND ROBERT L | Director | 09/30/2018 | 5,816 |
| Alafi Christopher D | Director | 09/30/2018 | 14,496 |
| LERNER RICHARD A | Director | 06/29/2018 | 13,747 |
| Alafi Christopher D | Director | 06/29/2018 | 14,489 |
| VAN NOSTRAND ROBERT L | Director | 06/29/2018 | 4,983 |
| RIGGS RORY B | Director | 06/29/2018 | 14,489 |
| VAN NOSTRAND ROBERT L | Director | 03/30/2018 | 4,989 |
| Alafi Christopher D | Director | 03/30/2018 | 14,482 |
| RIGGS RORY B | Director | 03/30/2018 | 14,482 |
| LERNER RICHARD A | Director | 03/30/2018 | 13,746 |
| Hineline Lawrence J. | VP of Finance CFO | 02/16/2018 | 326,543 |
| Hineline Lawrence J. | VP of Finance CFO | 02/15/2018 | 668,621 |
| Halstead Michael | SVP and General Counsel | 01/22/2018 | 459,765 |
| Vanover Kimberly E. | SVP, Clinical Development | 01/08/2018 | 13,479 |
| Mates Sharon | Chairman, President & CEO | 01/08/2018 | 115,438 |
| Mates Sharon | Chairman, President & CEO | 01/05/2018 | 192,270 |
| Vanover Kimberly E. | SVP, Clinical Development | 01/05/2018 | 20,583 |
| Davis Robert E | SVP, Chief Scientific Officer | 01/04/2018 | 17,394 |
| Hineline Lawrence J. | VP of Finance CFO | 01/05/2018 | 32,706 |
| Hineline Lawrence J. | VP of Finance CFO | 01/04/2018 | 50,019 |
| Halstead Michael | SVP and General Counsel | 01/05/2018 | 27,284 |
| Halstead Michael | SVP and General Counsel | 01/04/2018 | 41,895 |
| VAN NOSTRAND ROBERT L | Director | 12/29/2017 | 4,996 |
| RIGGS RORY B | Director | 12/29/2017 | 14,494 |
| LERNER RICHARD A | Director | 12/29/2017 | 13,742 |
| Alafi Christopher D | Director | 12/29/2017 | 14,494 |
| VAN NOSTRAND ROBERT L | Director | 12/29/2017 | 4,996 |
| LERNER RICHARD A | Director | 12/29/2017 | 13,742 |
| RIGGS RORY B | Director | 12/29/2017 | 14,494 |
| Alafi Christopher D | Director | 12/29/2017 | 14,494 |
| LERNER RICHARD A | Director | 12/11/2017 | 18,750 |
| LERNER RICHARD A | Director | 12/11/2017 | 105,630 |
| Davis Robert E | SVP, Chief Scientific Officer | 12/05/2017 | 9,750 |
| Alafi Christopher D | Director | 11/22/2017 | 155,500 |
| Mates Sharon | Chairman, President & CEO | 10/30/2017 | 28,125 |
| Mates Sharon | Chairman, President & CEO | 10/30/2017 | 295,313 |
| ALAFI MOSHE | 10% Owner | 10/02/2017 | 4,000,008 |
| Alafi Christopher D | Director | 10/02/2017 | 4,000,008 |
| ALAFI CAPITAL CO LLC | 10% Owner | 10/02/2017 | 4,000,008 |
| MARCUS JOEL S | Director | 01/26/2017 | 247,450 |
| Vanover Kimberly E. | SVP, Clinical Development | 01/05/2017 | 13,272 |
| Mates Sharon | Chairman, President & CEO | 01/05/2017 | 67,541 |
| Hineline Lawrence J. | VP of Finance CFO | 01/05/2017 | 31,800 |
| Halstead Michael | SVP and General Counsel | 01/05/2017 | 26,497 |
| Vanover Kimberly E. | SVP, Clinical Development | 12/15/2016 | 27,425 |
| Vanover Kimberly E. | SVP, Clinical Development | 12/15/2016 | 142,773 |
| ALAFI MOSHE | 10% Owner | 12/07/2016 | 336,038 |
| ALAFI MOSHE | 10% Owner | 12/06/2016 | 721,445 |
| Alafi Christopher D | Director | 12/07/2016 | 336,038 |
| Alafi Christopher D | Director | 12/06/2016 | 721,445 |
| ALAFI CAPITAL CO LLC | 10% Owner | 12/07/2016 | 336,038 |
| ALAFI CAPITAL CO LLC | 10% Owner | 12/06/2016 | 721,445 |
| ALAFI MOSHE | 10% Owner | 11/14/2016 | 492,969 |
| ALAFI CAPITAL CO LLC | 10% Owner | 11/14/2016 | 492,969 |
| Alafi Christopher D | Director | 11/14/2016 | 492,969 |
| RIGGS RORY B | Director | 02/05/2014 | 249,988 |
| RIGGS RORY B | Director | 02/05/2014 | 250,005 |
| Alafi Christopher D | Director | 02/29/2016 | 2,970,300 |
| LERNER RICHARD A | Director | 02/18/2016 | 13,600 |
| VAN NOSTRAND ROBERT L | Director | 12/31/2015 | 3,712 |
| RIGGS RORY B | Director | 12/31/2015 | 10,597 |
| MARCUS JOEL S | Director | 12/31/2015 | 10,704 |
| Alafi Christopher D | Director | 12/31/2015 | 10,489 |
| LERNER RICHARD A | Director | 12/31/2015 | 10,113 |
| Mates Sharon | Chairman, President & CEO | 12/11/2015 | 77,125 |
| Mates Sharon | Chairman, President & CEO | 12/11/2015 | 2,774,441 |
| Hineline Lawrence J. | VP of Finance CFO | 12/15/2015 | 50,750 |
| Hineline Lawrence J. | VP of Finance CFO | 12/14/2015 | 4,500 |
| Hineline Lawrence J. | VP of Finance CFO | 11/24/2015 | 3,000 |
| Hineline Lawrence J. | VP of Finance CFO | 12/15/2015 | 1,169,226 |
| Hineline Lawrence J. | VP of Finance CFO | 12/14/2015 | 1,146,140 |
| MARCUS JOEL S | Director | 12/08/2015 | 1,243,960 |
| MARCUS JOEL S | Director | 12/07/2015 | 2,126,628 |
| MARCUS JOEL S | Director | 12/04/2015 | 1,678,800 |
| Hineline Lawrence J. | VP of Finance CFO | 11/24/2015 | 275,000 |
| Fienberg Allen A. | VP of Business Development | 09/09/2015 | 17,000 |
| Fienberg Allen A. | VP of Business Development | 08/19/2015 | 303,000 |
| Fienberg Allen A. | VP of Business Development | 08/21/2015 | 6,060 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 06/08/2015 | 671,000 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 05/19/2015 | 58,250 |
| Fienberg Allen A. | VP of Business Development | 03/31/2015 | 7,500 |
| MARCUS JOEL S | Director | 03/31/2015 | 18,400 |
| Alafi Christopher D | Director | 03/11/2015 | 15,000,000 |
| Fienberg Allen A. | VP of Business Development | 01/14/2015 | 95,000 |
| Hineline Lawrence J. | VP of Finance CFO | 12/09/2014 | 190,558 |
| Hineline Lawrence J. | VP of Finance CFO | 12/08/2014 | 185,418 |
| Hineline Lawrence J. | VP of Finance CFO | 12/02/2014 | 18,600 |
| Alafi Christopher D | Director | 12/01/2014 | 20,975 |
| ALAFI MOSHE | 10% Owner | 12/01/2014 | 20,975 |
| ALAFI CAPITAL CO LLC | 10% Owner | 12/01/2014 | 20,975 |
| ALAFI CAPITAL CO LLC | 10% Owner | 11/28/2014 | 516,250 |
| ALAFI MOSHE | 10% Owner | 11/28/2014 | 516,250 |
| Alafi Christopher D | Director | 11/28/2014 | 516,250 |
| Mates Sharon | Chairman, President & CEO | 11/25/2014 | 25,000 |
| Mates Sharon | Chairman, President & CEO | 11/28/2014 | 516,250 |
| Alafi Christopher D | Director | 11/19/2014 | 14,735 |
| ALAFI MOSHE | 10% Owner | 11/19/2014 | 14,735 |
| ALAFI CAPITAL CO LLC | 10% Owner | 11/19/2014 | 14,735 |
| Alafi Christopher D | Director | 11/14/2014 | 2,004 |
| Alafi Christopher D | Director | 11/18/2014 | 50,246 |
| ALAFI MOSHE | 10% Owner | 11/18/2014 | 50,246 |
| ALAFI MOSHE | 10% Owner | 11/14/2014 | 2,004 |
| ALAFI CAPITAL CO LLC | 10% Owner | 11/18/2014 | 50,246 |
| ALAFI CAPITAL CO LLC | 10% Owner | 11/14/2014 | 2,004 |
| Alafi Christopher D | Director | 11/13/2014 | 33,264 |
| Alafi Christopher D | Director | 11/12/2014 | 76,150 |
| Alafi Christopher D | Director | 11/11/2014 | 77,750 |
| ALAFI MOSHE | 10% Owner | 11/12/2014 | 76,150 |
| ALAFI MOSHE | 10% Owner | 11/11/2014 | 77,750 |
| ALAFI MOSHE | 10% Owner | 11/13/2014 | 33,264 |
| ALAFI CAPITAL CO LLC | 10% Owner | 11/13/2014 | 33,264 |
| ALAFI CAPITAL CO LLC | 10% Owner | 11/12/2014 | 76,150 |
| ALAFI CAPITAL CO LLC | 10% Owner | 11/11/2014 | 77,750 |
| Halstead Michael | SVP and General Counsel | 11/06/2014 | 201,110 |
| Halstead Michael | SVP and General Counsel | 11/05/2014 | 106,470 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 10/16/2014 | 77,280 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 10/15/2014 | 30,060 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 10/13/2014 | 24,000 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 10/08/2014 | 71,175 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 10/06/2014 | 9,540 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 10/03/2014 | 237,945 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 09/15/2014 | 75,000 |
| Hineline Lawrence J. | VP of Finance CFO | 09/08/2014 | 150 |
| Hineline Lawrence J. | VP of Finance CFO | 09/08/2014 | 4,500 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 07/21/2014 | 18,750 |
| ALAFI MOSHE | 10% Owner | 06/19/2014 | 100,006 |
| Fienberg Allen A. | VP of Business Development | 05/28/2014 | 18,750 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 05/27/2014 | 75,000 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 05/22/2014 | 89,983 |
| RIGGS RORY B | Director | 02/05/2014 | 499,993 |
Load More Insider Transactions
FUNDS WITH A POSITION IN INTRA-CELLULAR THERAPIES, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 6,321,619 | 0.0098% | -21.74% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 1,686,173 | 0.01% | -18.36% | Other |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,565,996 | 3.94% | 63.26% | Growth At A Reasonable Price |
| HOLOCENE ADVISORS, LP | 1,479,675 | 0.42% | 62.76% | Growth At A Reasonable Price |
| D. E. SHAW & CO., INC. | 580,359 | 0.04% | 48.7% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 501,173 | 0.06% | -10.5% | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 406,714 | 0.05% | -0.95% | Event Driven |
| FARALLON CAPITAL MANAGEMENT LLC | 231,000 | 0.07% | Exited | Event Driven, Value |
| RENAISSANCE TECHNOLOGIES LLC | 222,400 | 0.03% | 129.99% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 215,439 | 0.14% | New | Growth |
| AQR CAPITAL MANAGEMENT LLC | 105,431 | 0.01% | 33.55% | Other |
| TUDOR INVESTMENT CORP ET AL | 51,901 | 0.02% | New | Event Driven, Other |
| TIG ADVISORS, LLC | 50,500 (Call) | 0.34% | Exited | Event Driven |
| ROYCE & ASSOCIATES LP | 37,500 | 0.02% | 66.67% | Value |
| ALPINE GLOBAL MANAGEMENT, LLC | 35,300 | 0.42% | New | Event Driven |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 17,000 | 0.07% | New | Value |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 15,000 (Put) | 0.00091% | New | Value |
| GOTHAM ASSET MANAGEMENT, LLC | 5,286 | 0.00469% | New | Other |
| MAVERICK CAPITAL LTD | 3,660 | 0.00476% | Exited | Growth At A Reasonable Price, Growth |
CHANGE IN SHARES OUTSTANDING FOR INTRA-CELLULAR THERAPIES, INC.
STOCK BUYBACKS FOR INTRA-CELLULAR THERAPIES, INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
12/31/2023
0.61%
1Q
09/30/2023
0.76%
2Q
06/30/2023
0.97%
3Q
03/31/2023
1.83%
4Q
12/31/2022
2.23%
5Q
09/30/2022
2.50%
6Q
06/30/2022
2.75%
7Q
03/31/2022
4.61%
8Q
12/31/2021
18.90%
9Q
09/30/2021
19.08%
10Q
06/30/2021
19.26%
11Q
03/31/2021
19.68%
12Q
12/31/2020
20.54%
13Q
09/30/2020
39.33%
14Q
06/30/2020
45.83%
15Q
03/31/2020
48.80%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR INTRA-CELLULAR THERAPIES, INC.
LOADING...